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Metabolomic signatures associated with complex disease have been identified.
Metabolomic profiling and the integration of genomic data have proven to be powerful tools
to investigate genetic effects underlying intermediate phenotype levels and may facilitate
improved understanding of pathophysiologic processes of disease. However, most published
studies did not consider sex as an effect modifier, analyze sex-specific effects, nor gene by
sex interactions. One reason can be incomplete knowledge of the power of statistical methods
used in a given dataset.
I first investigated sex-specific genetic effects by performing sex-stratified exomewide association studies for 271 chromatography-mass spectrometry measured metabolites in
the Atherosclerosis Risk in Communities (ARIC) study, followed by a conventional Z test to
evaluate the heterogeneity of genetic effects between men and women. We used AfricanAmericans as the discovery sample and pursued exome-wide significant (false discovery rate
Q≤ 5%) genes for replication in European-Americans. Overall, we identified and replicated
variants in 12 genes associated with metabolite levels, one of which, rs11555566 in ADA,

was a novel common variant suggesting a larger effect in men compared to women for
association with N1-methyladenosine levels.
I then focused on rare genetic variants and sex interactions on serum metabolite levels
and evaluated the joint effect of genetic main effects and gene-sex interactions in the same
discovery and replication population. Using gene-based rareGE and MiSTi approaches, we
observed and replicated 14 gene-metabolite associations through joint test, three of which
were novel, including PLA2G7- arachidonate (20:4n6), PTER- N-acetyl-beta-alanine and
NPC2- leucylserine. Significance of the NPC2- leucylserine association arose from both
genetic main effects and gene-sex interaction effects.
Finally yet importantly, I carried out a simulation study to investigate the
performance of two aforementioned emerging methods in detecting rare variant gene-sex
interaction effects on a quantitative phenotype. Compared with conventional burden tests,
rareGE and MiSTi have more power under a wide range of scenarios. Simulation results also
illustrate that an approach that jointly tests the genetic main effects and gene-sex interactions
increases statistical power and has the potential to uncover novel genetic signals that have not
been identified previously.
In conclusion, our study suggests sex-specific genetic effects on the metabolome, and
reports novel genetic variants associated with metabolite levels. Use of simulated data
provides insights into the power and desired sample size in conducting rare variant G×E
interaction studies for these newly introduced methods, justify their use in practice.
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CHAPTER I. BACKGROUND
Literature Review
Sex Difference in Cardiovascular Disease
Cardiovascular disease (CVD) remains the leading cause of mortality across race
groups for both women and men in the United States (1), but there are substantial sex
differences in the prevalence and presentation of different CVD (Figure I-1). The percentage
of adult men living with major manifestations of CVD exceeds those of adult women, except
for stroke. Men develop coronary artery disease (CAD) earlier and usually present with more
severe atherosclerosis in their coronary arteries than women, but the risk of heart failure and
mortality rate following myocardial infarction is higher in women than men (2, 3). Despite
unfavorable progression of CVD, women may be less likely to receive optimal diagnosis and
timely treatment because the presentation of symptoms in women with acute coronary
disease is “atypical”- women are significantly less likely to report chest pain or discomfort
compared with men (4). Although sex differences in prevalence, age of onset, progression
and outcome of CVD have been well-documented (5), the biological underpinnings of these
differences are not well-understood.
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Figure I-1 Sex difference in cardiovascular disease (CVD) at a glance

Note: Data adapted from Heart disease and stroke statistics 2017 update: a report from the
American Heart Association (5)

Sex differences in the epidemiology of CVD may arise from different exposures of
environmental and lifestyle risk factors, for instance, heavy alcohol consumption, tobacco
use, and physical inactivity (6, 7). In addition to differences in health-related lifestyles, to
understand the biological determinants of observed sex differences in CVD, a natural starting
point is the biological effects of the sex chromosomes (8), and related sex hormones effects,
such as estrogen levels (9). However, it is also important to consider genetic variants on the
autosomes that may affect risks of developing CVD differently in women and men. Previous
studies have identified different genetic variants influencing CVD risk in men compared to
women, or found significant genotype-sex interactions for CVD or related traits (10-13). For
example, Silander et al. reported that variants in CPB2 and USF1 genes have a female2

specific risk for coronary heart disease (CHD) and/or CVD, while a variant (rs2069840) in
IL6 shows strong association with CVD in men but not in women (12). In a large study of
more than 200,000 individuals, 49 loci were found to be associated with waist-to-hip ratio, an
independent risk factor to CVD; 20 of the 49 loci show significant sexual dimorphism, 19 of
which present a stronger effect in women (13).
Despite previously reported sexually dimorphic genetic-disease associations (14),
most large published meta-analyses (15-19) do not take sex differences into account beyond
adjusting for sex as a covariate (15, 19, 20). Thus, potential sex differences are important
components for further genetic epidemiologic research of CVD and its risk factors.

Gene-Environment Interactions
Traditional genome-wide association studies (GWAS) utilizing common genetic
variants have successfully identified a large number of loci associated with complex diseases
and traits. However, a large proportion of the heritability of these diseases/traits remains
unexplained (21). To find the “missing heritability”, rare variants, structural variations, as
well as gene-environment (G×E) interactions have been suggested to extend beyond straightforward genome-wide association approaches (22).
Gene-environment interactions are defined in this proposal as different effects of a
genotype on disease risk between differing environmental exposures, including sex.
Equivalently, GxE interactions may be defined by different effects of an environmental
exposure on disease risk in persons with different genotypes (23, 24). Studying G×E
3

interactions is important, as it may extend our knowledge of the genetic architecture of
complex traits and improve our understanding of the underlying mechanisms of common
diseases for novel and known loci (25-27). Although premature at this point, knowledge of
gene-sex interactions could lead to different genetic risk algorithms and treatment
recommendation in men compared to women.
Since 2010, several large-scale genome-wide G×E studies have successfully
identified novel loci accounting for the modifying effects of environmental exposures such as
age, sex, BMI, alcohol consumption, smoking status on CVD-related intermediate traits (2837). Although none of the studies directly model clinical defined CVD, using risk factors
such as blood pressure, lipid profiles, and obesity, these studies have successfully identified
novel common variant loci related to CVD risk that were not detected via analysis of main
effects alone. For example, a genome-wide meta-analysis of 114 studies in up to 320,485
European-ancestry individuals reported 4 novel loci for BMI that showed age-specific
effects, and 17 novel loci with sex specific effects on BMI (29). Though it is tempting to
consider conducting an association test within each stratum of environmental exposures, a
recent study (38) compared a stratified analysis approach and a 2 degree of freedom (DF)
joint test for studying G×E interactions and suggested that inclusion of G×E interactions is
important in terms of identifying novel signals, particularly for rare and low-frequency
variants.
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Rare Variant G×E Interactions
Availability of high throughput DNA sequencing technologies and large-scale
imputation reference panels (39) offer an opportunity to investigate rare and low-frequency
genetic variants with minor allele frequency (MAF) ≤5% across the genome. Analysis of
G×E interactions involving rare variants may identify novel loci, and characterize rare
variant G×E interactions in previous loci identified by GWAS of common variants. However,
unlike well-established G×E interaction tests for common variants (40, 41), methods
development for detecting rare variant G×E interactions is challenging for several reasons.
First, considering typical sample sizes of most published GWAS studies, a single marker test
is underpowered for rare and low frequency variants. Second, conventional burden tests that
simply summarize the total number of variants within a region and fit a model for the rare
variant burden by environment interaction term, often result in inflated type 1 error rates and
biased estimates when the rare variants and environment are not independent (i.e. G×E
correlation) (42).
Recently developed novel approaches for testing rare variant G×E interaction effects
(42-47) face limitations. Jiao and colleagues (45, 46) treated genetic main effects as fixed
effects, which may suffer from inflated type I error. Lin et al proposed an interaction
Sequence Kernel Association Test (42) that is powerful when both positive and negative
directions of G×E effects exist, yet loses power when the variants in the set have the same
direction of G×E. Finally, Tzeng (43) assumed comparable magnitude of the variance
component parameters for genetic main effects and G×E interactions, which may not be true.
5

Further work is underway to overcome the aforementioned limitations. Su et al.
proposed a novel and rigorous framework to derive independent score statistics for fixed
effects and the variance component that is more powerful to test G×E interaction terms of
rare variants (48). A joint test that allows one to simultaneously test genetic main effects and
interaction effects and requires no assumption about the magnitude of the variance
component parameters for the genetic main effects and G×E interactions was proposed and
successfully implemented by Chen and colleagues (49). The former interaction-only test
allows detecting G×E interactions regardless of the genetic main effect, while the latter joint
testing approach aims to detect associated genetic effects allowing for G×E interactions.
Applying these newly developed methods to study rare variant G×E interaction in CVDrelated traits, for instance the metabolomic data that will be reviewed in the next section, may
improve our understanding of the underlying pathophysiology of disease.

Metabolomics and the metabolome by sex
Metabolomics is one of the “-omics” disciplines that systematically studies smallmolecule metabolites found in biological samples, such as cells, biofluids, tissues or
organisms. These metabolites are produced and modified by a variety of chemical and
physiologic processes, such as amino acid and lipid biosynthesis, carbohydrate anabolism,
and xenobiotic metabolism. The entire ensemble of small-molecule metabolites presented in
a biological sample is generally referred as the metabolome. These small-molecule

6

metabolites may reveal pathologic or etiologic pathways to complex diseases because they
represent intermediates that profile biological status closely related to phenotypes (50).
At present, there are two major instrument platforms for measuring metabolite levels
in biological samples, namely nuclear magnetic resonance (NMR) and chromatography
combined with mass spectrometry (MS)-based metabolic profiling (51-53). There are also
two major distinct technologic approaches, “untargeted” and “targeted”, to metabolite
measurements (54). Untargeted metabolomics aims to analyze all of the measureable analytes
in a sample including unknown chemicals, and targeted metabolomics means to measure an a
priori defined group of chemically characterized metabolites (e.g. lipids). Several review
papers have described and contrasted these platforms and approaches (55, 56).
Acknowledging concerns about the semi-quantitative nature of the untargeted MS-based
approach, it has notable advantages for detecting and quantifying (at least relative
quantification) as many metabolites as possible in a biological sample with high sensitivity.
Therefore applying such an approach is able to achieve high-throughput profiling of the
metabolome.
In the past few years, numerous epidemiological studies utilizing metabolomics have
successfully linked metabolite levels to the etiology and progression of complex diseases
such as hypertension, CVD and diabetes in individuals with and without European-ancestry
(57-69). The identified CVD metabolomic signatures include dietary phosphatidylcholine
metabolites, acylcarnitines (61, 65), as well as several other lipid classes such as
polyunsaturated fatty acids (FAs) (66, 68, 69). Such metabolomic signatures were involved
7

in CVD risk via various potential mechanisms. For example ω-3 FAs may prevent
arrhythmias, lower heart rate and blood pressure, decrease platelet aggregation, and lower
triglyceride levels (70). The latter is accomplished by reducing hepatic very-low-density
lipoprotein and triglycerides synthesis and secretion and enhancing the triglycerides
clearance from chylomicrons (71, 72).
In addition, both traditional GWAS and sequence analyses across the whole genome
or exome have successfully identified and verified hundreds of genetic loci associated with
metabolite levels (73-85), and many of them can be further linked to clinically relevant
factors of disease development. An example of integrating genomics and metabolomics to
promote novel biomarker discovery and better understand etiologic pathways of complex
disease is the story of hexadecandioate. In a whole exome sequencing study of AfricanAmericans, Yu et al. identified a loss-of-function (LoF) variant in SLCO1B1 that was
associated with increased levels of hexadecanedioate, which for the first time, was reported
for its relationship with heart failure risk (81). Hexadecanedioate, a long-chain dicarboxylic
acid, was also reported to be significantly associated with increased blood pressure and
mortality (59, 81). The aforementioned genetic and metabolomic evidence together
implicated a potential pathway for heart failure and opened up the possibility of further
hypothesis tests and experimental studies.
Limited work has been done that shows that the metabolomic profiles of men and
women are different, and sex-specific metabolism-related genetic polymorphisms have been
identified through sex-stratified GWAS in European-ancestry populations (86, 87). Pathway
8

analysis has revealed gender-specific pathway differences in the serum metabolome (87).
Moreover, a single-nucleotide polymorphism (SNP) in CPS1 rs715 that previously showed a
strong sex difference in association with glycine (86), yields a strikingly significant and
protective association with decreased risk of CAD only in women (88). Metabolomics
studies also reveal the sex-specific effects of a SNP rs646776 in SORT1, a known lowdensity lipoprotein cholesterol locus (89). Additional systematic studies are needed to better
understand the modifying effect of sex on the human metabolome and its genetic
determinants with a particular focus on rare variants. Additionally, current understandings of
sex differences in the metabolome have solely originated from studies in European-Ancestry
populations and there is a need for expanding these studies to underrepresented populations,
such as African-Americans (AAs).

9

Public Health Significance
There are encouragements from the National Heart, Lung, and Blood Institute
(NHLBI) for conducting additional research addressing the public health concerns of sex
differences in cardiovascular diseases (90). Although significant sex-related differences in
CVD epidemiology are appreciated (1, 5), less effort has been devoted to uncovering its
etiology. Studies that go beyond common single nucleotide variants to investigate the role of
rare genetic variants as well as studies with more complex statistical analyses to evaluate the
impact of sex alteration of disease phenotypes are warranted.
It is generally accepted that complex diseases such as CVD are not only caused by
genetic or environmental factors alone, but also the interactions between them (26). Serum
metabolite levels ultimately are the reflections of functional activities of genes and
environmental exposures (91, 92). Given the nature of metabolite levels and numerous
aforementioned work that have linked metabolites to complex diseases, they can serve as
ideal intermediates to understand the effects of G×E interactions on complex diseases. Rare
and low frequency (MAF≤5%) variants make up the vast majority of the genetic variation in
the genome (93), and may account for part of the missing heritability along with G×E
interactions (22). Studying the integration of rare and low frequency genetic variants, sexual
dimorphism, and metabolomics may improve our comprehensive understanding of the
underlying pathophysiology. To date, there is no study systematically utilizing and
comparing methods developed for testing rare variant G×E interactions in large-scale human
population data. In addition, investigating gene-sex interactions or sex-specific genetic
10

variants related to CVD-related traits has not been done in AAs. New studies focusing on
AAs will help address this important knowledge gap.
This dissertation research leverages existing data from a large population-based
multi-ancestry cohort: the Atherosclerosis Risk in Communities (ARIC) study that contains
well-characterized AA and European-American (EA) participants to investigate whether
there are sex-specific differences in the genetic determination of serum metabolome levels.
As mentioned above, the serum metabolome may serve as an ideal surrogate/biomarker for
disease status, including CVD. Therefore, Chapter 2 of this dissertation describing the sexspecific genetic effects on the serum metabolome responds to the aforementioned rising
public health concerns on sex-related differences in CVD-related phenotypes (20, 22, 90).
Chapters 3 and 4 address the challenge of testing rare variant G×E interactions through
estimating gene-sex interactions on the serum metabolome with a particular focus on rare and
low-frequency genetic variants using two emerging methods, and comparing the power of
differing methods in simulation studies. Chapter 5 presents a summary of the findings and a
perspective about further rare and low-frequency genetic variant G×E interaction studies.
The results of this dissertation are expected to offer new evidence about sex-specific
genetic influences on the human metabolome and report novel genetic variants that were not
previously identified when gene-sex interaction parameters were omitted in previous studies.
This dissertation will also provide insights into the power and desired sample size for
conducting rare variant G×E interaction studies, which may advance the understanding of
current G×E interaction results and benefit future studies.
11

CHAPTER II.

SEX-SPECIFIC GENETIC EFFECTS ON THE SERUM

METABOLOME IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC)
STUDY
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Abstract
Metabolomic signatures associated with complex disease, such as cardiovascular
disease, have been identified. Metabolomic profiling and the integration of genomic data
have proven to be powerful tools to investigate genetic effects underlying intermediate
phenotype levels and may facilitate improved understanding of pathophysiologic processes
of disease. However, most published studies did not consider sex as an effect modifier,
analyze sex-specific effects, nor gene by sex interactions. This study investigated sexspecific genetic effects on serum metabolite levels and evaluated the estimated heterogeneity
of genetic effects between men and women. We analyzed 3,540 individuals from the
Atherosclerosis Risk in Communities (ARIC) study with metabolite measurements and
exome chip genotyped data. We performed sex-stratified exome-wide association studies for
271 chromatography-mass spectrometry measured metabolites in ARIC African-Americans
as the discovery sample and pursued exome-wide significant (false discovery rate Q<5%)
genes for replication in European-Americans. We identified and replicated variants in 12
genes through either common single variant analysis or gene-based burden tests in sexstratified exome-wide association analyses. For example, rs11555566 in ADA is a novel
common variant associated with N1-methyladenosine levels. Results of rs11555566
suggested a larger effect in men (estimated effect size 0.18-0.22) as compared to women
(estimated effect size 0.14-0.17), but the difference was not significant. Variants in 6 genes
suggested differing genetic effects on metabolite levels observed through testing for
difference of the effect size estimates in sex-stratified results, although the difference
13

between sexes was not replicated. Our study suggests that sex-specific genetic effects of
metabolites may exist, but the lack of consistency in testing sex differences of the genetic
effects between discovery and replication samples underscores that future studies should
consider sex-specific effects with enhanced statistical methods and tools.
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Introduction
Metabolomics is one of the “-omics” disciplines that systematically studies smallmolecule metabolites found in biologic samples such as cells, biofluids, tissues or organisms.
These metabolites are produced and modified by a variety of chemical and physiologic
processes, such as amino acid and lipid biosynthesis, carbohydrate anabolism, and xenobiotic
metabolism. The ensemble of small-molecule metabolites presented in a biologic sample is
referred to as the metabolome. These small-molecule metabolites may reveal pathologic or
etiologic pathways to complex diseases because they represent intermediates that at least
partially profile the biological status of an individual and are closely related to a number of
risk factor and disease-related phenotypes (1).
Numerous epidemiologic studies utilizing metabolomics have successfully related
metabolite levels to the etiology and progression of complex diseases such as hypertension,
cardiovascular disease CVD, and diabetes in both Whites and non-Whites (2-14). In addition,
both traditional genome-wide association studies (GWAS) and sequencing analyses across
the whole genome or exome have successfully identified and verified hundreds of genetic
loci with metabolite levels (15-25), and many of them can be further linked to clinically
relevant factors of disease development. An example of integrating genomics and
metabolomics to promote novel biomarker discovery and better understand the etiological
pathways of complex disease is the story of hexadecandioate. In a whole exome sequencing
study of African-American population, Yu et al. identified a loss-of-function (LoF) variant in
SLCO1B1 that was associated with increased levels of hexadecanedioate, which for the first
15

time, was reported to be associated with incident heart failure (23). Hexadecanedioate, a
long-chain dicarboxylic acid, was also reported to be significantly associated with increased
blood pressure and mortality (4, 23). The aforementioned genetics and metabolomics
evidence together implicated a potential novel pathway for heart failure and opens up the
possibility of further hypothesis testing and experimental studies.
Limited work has shown that the metabolomic profiles of men and women are
different, and sex-specific metabolism-related genetic polymorphisms have been identified
through sex-stratified GWAS (26, 27). Pathway analysis has also revealed sex-specific
pathway differences in the serum metabolome (27). Moreover, a single-nucleotide
polymorphism (SNP), rs715 in CPS1, that previously showed a strong sex difference in
association with glycine (26), yields a strikingly significant and protective association with
decreased risk of coronary artery disease only in women (28). Metabolomics studies also
reveal the sex-specific effects of a SNP rs646776 in SORT1, a known low-density lipoprotein
cholesterol locus (29). Additional and systematic studies are needed to better understand the
modifying effect of sex on the human metabolome and its genetic determinants. Additionally,
current understanding of sex differences in the metabolome has solely originated from
studies in Whites, and there is a need for expanding these studies to underrepresented
populations, such as African-Americans (AAs). Therefore, we investigated whether there are
sex-specific differences in the genetic effects on the metabolome using a subset of AAs in the
Atherosclerosis Risk in Communities (ARIC) study, and examined the replication of these
sex-specific effects in European-Americans (EAs) from the ARIC study.
16

Methods
Study Sample
The ARIC study is a population-based prospective cohort study of 15,792 adults from
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN;
and Washington County, MD), which has been described in detail previously (30). ARIC
included both EAs and AAs aged 45-64 at the baseline examination (1987-1989).
Participants completed three additional triennial follow-up examinations, a fifth exam in
2011-2013, and a sixth exam in 2016-2017. Included in this analysis were 3,540 participants
with metabolite measurements and exome chip genotyped data at the baseline examination.
The ARIC study has been approved by the institutional review boards at each site, and
written informed consent was obtained from all participating individuals.

Measurements of Metabolites
Metabolite profiling was completed in 2010 (batch 1) and 2014 (batch 2) using
fasting serum samples that had been stored at -80°C since collection at the baseline
examination. Batch 1 were all AAs and Batch 2 included both AAs (24.8%) and EAs
(75.2%). In total, 602 metabolites were detected and semi-quantified by Metabolon (Durham,
USA) using untargeted, gas- and liquid- chromatography-mass spectrometry (GC-MS and
LC-MS)-based protocols (31, 32). To evaluate batch effects, a set of 97 samples were
measured in both the 2010 and 2014 batches. There were 384 named metabolites that were
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identified to be present in both batches and these metabolites will be used for this thesis
research.
In the present study, sample-level quality control was performed to remove
individuals with missing values for more than 40% of the measured metabolites (1 sample
was removed from batch 2). After sample-level quality control, metabolomic profiles were
available in 2479 AAs and 1553 EAs. Exclusion criteria for metabolites includes: 1) six-there
metabolites were excluded as more than 40% of the samples have missing values or values
below the detection limit (BDL) within each batch; and 2) fifty metabolites were excluded as
the Pearson correlation coefficient (r) between 2010 and 2014 measurements on the same
stored sample (at least 46 out of the 97 pairs) is less than 0.30. Thus, this study was based on
an evaluation of 271 named metabolites. Metabolite levels were analyzed as continuous
variables, where missing/BDL values were imputed using random forest imputation based on
the remaining observed measurements (33, 34).

Genotypes
Genotyping was performed with the Illumina HumanExome BeadChip v1.0 (“exome
chip”) querying 247,870 single nucleotide variants (SNVs) at the baseline examination in
11,071 EAs and 2,953 AAs in the ARIC study. The exome chip data was selected rather than
sequence data that is also available in ARIC because using exome chip data maximizes the
available sample size for this proposed analysis. To improve accurate calling of rare variants,
genotyped data from ARIC along with 10 other studies from the Cohorts for Heart and Aging
18

Research in Genomic Epidemiology (CHARGE) Consortium were pulled together for joint
calling, details were described elsewhere (35). A total of 8,994 variants were excluded after
laboratory quality control steps, for instance call rate <95%, Hardy-Weinberg equilibrium
test P value (pHWE) < 1×10-6, and poorly clustering variants (35). SNVs with missing rate
>5% were removed from analysis.
Exome chip variant annotation was completed using the Whole Genome Sequencing
Annotation (WGSA) pipeline v055 (36), including dbNSFP v2.9 (37). Functional variants
and genes were determined using ANNOVAR (38) according to the reference genome
GRCh37/hg19 and National Center for Biotechnology Information RefSeq.

Statistical Analyses
Metabolite levels were winsorized (99%) within each batch, respectively. Due to
right-skewed distributions of many metabolite levels, natural log transformation was applied
to most metabolites prior to analyses. For metabolites that were still not normally distributed,
a rank based inverse normal transformation was used. The transformation methods applied to
each metabolite are provided in Appendix A- Supplemental Table 1.
Race-specific exome-wide association studies for each metabolite level were
conducted in men and women separately. Linear regression analyses were performed for the
continuous metabolite levels. For common variants with MAF>5%, single variant association
tests assuming an additive genetic model were conducted. Because our primary focus was on
rare and low-frequency variants, we aggregated rare and low-frequency variants (MAF ≤
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5%) in groups based on a gene’s exons using burden tests (39). The unit-of-analysis is an
annotated gene. All annotated coding variants, such as splicing, stop-gain, stop-loss,
nonsynonymous, and indels within the gene were aggregated for the analysis. Genes with
cumulative minor allele count < 3 within men or women of each race group were not
analyzed. Models were adjusted for age and population substructure using the first three
ancestry principal components (PCs) (40), with additional adjustment for estimated
glomerular filtration rate (eGFR) and batch effects for metabolites.
To test each SNV/gene and metabolite for difference of the effect size estimates for
the SNV/gene calculated in the sex-specific analyses, we used an approximately normally
distributed test statistic, Z (41). This Z test was selected as opposed to a sex-pooled
multiplicative interaction test because traditional linear regression assumes homoscedasticity
across all combinations of G and E which is often violated for rare variant burden test (42).
𝑍=

𝛽̂𝑚𝑒𝑛 − 𝛽̂𝑤𝑜𝑚𝑒𝑛
√𝑠𝑒(𝛽̂𝑚𝑒𝑛 )2 + 𝑠𝑒(𝛽̂𝑤𝑜𝑚𝑒𝑛 )2

We used AAs as the discovery sample and conducted replication in EAs. Using a
false discovery rate (FDR) to correct for number of genes/SNV tested while considering the
271 metabolites, we defined exome-wide significant genes/SNVs as those with FDR Q ≤ 5%
in discovery AAs; these genes/SNVs were pursued for replication analyses in EAs.
Replication was defined as those genes/SNVs with consistent directions of the effect, and
FDR Q ≤5%, corrected for the number of genes/SNVs taken forward to evaluate in EAs. All
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statistical analyses were conducted in R version 3.4 (R Foundation for Statistical Computing,
Vienna, Austria).

Results
We conducted sex-specific exome-wide association analyses in 1292 women and 720
men among ARIC AAs. A total of 827 EA women and 701 EA men were analyzed for
replication. The baseline characteristics of both men and women in AAs and EAs were
shown in Table II-1. The average age of women and men were comparable in both AAs
(52.9 ± 5.6 vs. 53.0 ± 5.8 years) and EAs (54.3 ± 5.8 vs. 54.9 ± 5.8 years).

Common single variant results
Sex-stratified exome-wide association analysis identified and replicated (across race
groups) common variants in 9 genes (ADA, ALMS1, DMGDH, DUSP11, FBX07, GCKR,
KLKB1, LACTB, and VNN1) that were shown to be associated with metabolite traits in
women. Common variants in the first four genes (ADA, ALMS1, DMGDH and DUSP11)
were significant and replicated (across race groups) in men (Appendix A- Supplemental
Table 2-3, Figure II-1). Eight out of the nine observed significant genes were consistent with
those previously identified through analyses using pooled samples of men and women. One
novel missense variant rs11555566 (ADA) with MAF ~6.2% - 7.8% was associated with N1methyladenosine in women (AA: 𝛽̂ = 0.14 p = 2.44×10-11 FDR Q = 4.67×10-6, EA: 𝛽̂ = 0.17
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p = 7.55×10-5) and men (AA: 𝛽̂ = 0.18 p=2.09×10-7 FDR Q = 0.04, EA: 𝛽̂ =0.22 p=9.71×106

), respectively.
In order to reveal sex–specific effects, we evaluated the estimated common genetic

effects for heterogeneity between men and women. One common variant, rs3746414
(ZFP64) showed a significant (p = 1.42×10-8, FDR Q = 0.05) difference between men and
women for its association with propanediol in AAs. The significant association between
rs3746414 and propanediol was only observed in AA men (𝛽̂ = -0.30, p = 7.00×10-10). For
AA women, the observed effect was positive but not significant (𝛽̂ = 0.04, p = 0.22).
Although we observed a similar difference in the direction of effects in EAs (negative effect
in EA men and positive effect in EA women, data not shown), the sex-difference in genetic
effects of rs3746414 on propanediol was not significantly replicated in EAs.

Gene based rare and low-frequency variants
For the gene-based approach, we report four known metabolite genes (ACAD8,
CCBL1, ACY1 and DMGDH) that were successfully identified and replicated in female-only
burden tests. The latter two (ACY1and DMGDH) pass the significance thresholds of
identification and replication using male-only burden tests as well (Appendix ASupplemental Table 4, Figure II-1). In the Z tests that evaluated the aggregated gene effects
for heterogeneity between men and women, we observed significance (FDR Q<0.05) sex-

22

difference in genetic effects of five genes on metabolites in AAs, however, none of them was
successfully replicated in EAs (Appendix A- Supplemental Table 5).

Discussion
We performed sex-stratified exome-wide association analyses for 271 GC-MS/LCMS measured named metabolites in ARIC AAs, and identified a novel common variant
rs11555566 in the ADA gene associated with N1-methyladenosine levels in both men and
women. The association between rs11555566 and N1-methyladenosine levels was
successfully replicated in independent samples of ARIC EA men and women, respectively.
In AAs, we observed variants in 6 genes using common single variant tests or burden tests
suggesting differed genetic effects on metabolite levels through testing for difference of
effect sizes in sex-stratified results, although the difference between sexes was not shown to
be consistent in an independent sample of EAs.
In total, we identified and replicated variants in 12 genes through either common
single variant analysis or gene-based burden test in sex-stratified analyses. Eleven of them
were previously reported genes known to be associated with one or more metabolites in nonsex-stratified genetic association studies (16, 19, 21, 22). Variants in 6 genes reached FDRcorrected exome-wide significance for testing the difference of effects between men and
women but we failed to replicate the sex differences in EAs. A previously reported sexspecific genetic effect of a non-coding variant in CPS1 associated with glycine (26) was not
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observed in our data. One difference between the analysis presented by Mittelstrass et al. (26)
and that presented here is we focused on only coding functional variants in our analyses.
In the results presented here, we identified a novel variant rs11555566 in the ADA
gene to be association with N1-methyladenosine. ADA encodes the enzyme, adenosine
deaminase that catalyzes the hydrolysis of adenosine to inosine and plays a critical role in
purine metabolism and adenosine homeostasis (43, 44). The metabolite we observed to be
associated with rs11555566, N1-methyladenosine, is one of the modified nucleosides that
contains adenosine as its core base. N1-methyladenosine modification regulates transfer
ribonucleic acid (tRNA) and messenger RNA (mRNA) stability (45, 46), and impacts a wide
array of gene expression (47). Although ADA’s primary function is developing and
maintaining the immune system in human (48), the metabolic basis and full physiological
role of ADA is not completely understood. Evidence has been reported for a role of ADA in
male fertility (49, 50). Our results suggest a slightly larger effect in men (𝛽̂ =0.18, 0.22 in
AAs and EAs, respectively) as compared to women (𝛽̂ =0.14, 0.17 in AAs and EAs,
respectively).
There may be lack of consistency in testing sex differences of genetic effects between
AAs and EAs due to: 1) the genetic architecture of the serum metabolome is consistent
between men and women, and/or- 2) a lack of statistical power to detect small differences in
genetic effects between men and women. Sex-stratified analyses followed by a z test testing
for difference of effect sizes may not be powerful enough to test sex difference in genetic
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effects on metabolome, particularly for rare and low-frequency genetic variants. Enhanced
statistical methods and tools with sufficient power and flexibility for testing heterogeneity of
genetics effects are needed. Finally, our study’s design with discovery in one race group and
replication in another may not be ideal. The discovery sample for this study was AAs, a
population with high level of genetic diversity to promote novel findings (51). However, the
replication sample was EAs. Rare variants aggregated in genes may differ between the two
races, and ancestry-specific rare variants may contribute to sex-specific effects on
metabolites, which will not be consistent between races and missed in our analyses.
In summary, we identified a novel variant in ADA associated with N1methyladenosine levels in both race groups, suggesting that sex-specific genetic effects of
metabolites may exist. The lack of consistency in testing sex differences of the genetic
effects between discovery and replication samples underscores that enhanced statistical
methods and tools are warranted for further sex-specific effect studies.
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Table II-1 Baseline characteristics of analyzed participants in the ARIC study
Women
Men
AAs

EAs

AAs

EAs

N

1292

827

720

701

Age (years)

52.9

54.3

53.0

54.9

(5.6)
eGFR
(mL/min/1.73 m²)

(5.8)

105.5

92.0

(18.6)

(14.9)

(5.8)
101.2
(17.8)

(5.8)
90.5
(14.2)

AAs: African-Americans, EAs: European-Americans, eGFR: estimated glomerular filtration
rate
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Figure II-1 Significantly identified and replicated gene-metabolite pairs revealed by sexstratified exome-wide association studies.
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CHAPTER III.

RARE AND LOW-FREQUENCY GENETIC VARIANT × SEX

INTERACTIONS IDENTIFY NOVEL LOCI INFLUENCING THE SERUM
METABOLOME IN THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC)
STUDY
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Abstract
Metabolomic profiling and the integration of genomic data have proven to be
powerful tools to investigate genetic effects underlying intermediate phenotype levels such as
metabolites and may facilitate improved understanding of pathophysiologic processes of
disease. However, most published studies did not consider sex as an effect modifier nor gene
by sex interactions. The present study investigated rare and low-frequency genetic variants
(minor allele frequency ≤ 5%) and sex interactions on serum metabolite levels and evaluated
the joint effects of genetic main effects and gene-sex interactions. Chromatography-mass
spectrometry measured metabolites and the Illumina HumanExome BeadChip genotyped
exonic variants were analyzed in 2,012 African-Americans from the Atherosclerosis Risk in
Communities (ARIC) study. Using gene-based rareGE and MiSTi approaches, we conducted
exome-wide gene-sex interaction tests, and a joint analysis of genetic main and gene-sex
interaction effects. Rare and low-frequency functional variants, (i.e. frameshift,
nonsynonymous, stop/gain, stop/loss, and splicing) were aggregated by genes. Exome-wide
significant genes (false discovery rate ≤ 5%) were evaluated for replication in an independent
sample of 1,528 ARIC European-Americans. In total, we observed and replicated 14 genemetabolite associations through the joint test, 3 of which were novel, including PLA2G7arachidonate (20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine. The NPC2leucylserine association arose from both genetic main effects and gene-sex interaction
effects, as the interaction test using rareGE for NPC2-sex interaction on leucylserine levels
reached nominal significance level (p = 3.79×10-04). In conclusion, this study applied
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emerging statistical approaches to investigate the role of rare and low-frequency genetic
variants and gene-sex interactions, and successfully identified novel genes associated with
metabolites.
Introduction
Metabolomics is a scientific approach that systematically evaluates small-molecule
metabolites in biologic samples that reflect the state of the system or whole organism and
may provide additional insights into disease pathology (1-3). Both traditional genome-wide
association studies (GWAS) and sequencing analyses across the exome or whole genome
have successfully identified and verified hundreds of genetic loci associated with the levels
of metabolites (4-16), and many of them can be further related to complex diseases or
clinically relevant risk factors of disease development (12, 17).
Sex-specific differences in metabolite patterns in healthy human have been reported
in urine and plasma (18, 19), which suggests that sex should be considered further in
metabolomic studies. Limited work has identified sex-specific metabolism-related genetic
polymorphisms through sex-stratified GWAS and sex-specific pathway differences in the
serum metabolome (20, 21). Additional systematic studies are needed to better understand
the modifying effect of sex on the human metabolome and its genetic determinants with a
particular focus on rare and low frequency (MAF ≤ 5%) variants. Rare and low frequency
variants make up the vast majority of the genetic variation in the genome (22), and may
account for part of the missing heritability along with gene-environmental (G×E) interactions
(23).
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Unlike well-established G×E interaction tests for common variants (24, 25), methods
development for detecting rare variant G×E interactions is challenging because of relatively
low power for a single marker test with MAF ≤5%, as well as inflated type 1 error rates and
biased effect estimates for conventional burden tests (26). Emerging methods have been
proposed to overcome these challenges. Su et al. proposed a novel and rigorous framework,
Mixed effects Score Tests for interaction (MiSTi), to derive independent score statistics for
fixed effects and the variance component that is more powerful to test G×E interaction terms
of rare variants (27). A joint test that allows one to simultaneously test genetic main effects
and interaction effects was proposed and successfully implemented by Chen and colleagues
in the R package ‘rareGE’ (28).
To date, there is no study systematically utilizing methods developed for testing rare
variant G×E interactions in the setting of large-scale metabolomic data. In addition, an
investigation of gene-sex interactions or sex-specific genetic variants related to metabolites
has not been conducted in African-Americans (AAs). Therefore, in this study, we leveraged
existing data from a large population-based multi-ancestry cohort, the Atherosclerosis Risk in
Communities (ARIC) study that contains well-characterized AAs and European-Americans
(EAs), to identify novel genetic loci influencing the serum metabolome that were not
identified when considering the genetic main effect alone.
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Methods
Study Sample
The ARIC study is a population-based prospective cohort study of 15,792 adults from
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN;
and Washington County, MD), which has been described in detail previously (29). ARIC
included both EAs and AAs aged 45-64 at the baseline examination (1987-1989).
Participants completed three additional triennial follow-up examinations, a fifth exam in
2011-2013, and a sixth exam in 2016-2017. There were 3,540 participants with complete
metabolite measurements and exome chip genotyped data at the baseline examination. The
ARIC study has been approved by the institutional review boards at each site, and written
informed consent was obtained from all participating individuals.

Measurements of Metabolites
Metabolite profiling was completed in 2010 (batch 1) and 2014 (batch 2) using
fasting serum samples that had been stored at -80° since collection at the baseline
examination. Batch 1 were all AAs and Batch 2 included both AAs (24.8%) and EAs
(75.2%). In total, 602 metabolites were detected and semi-quantified by Metabolon (Durham,
USA) using untargeted, gas- and liquid- chromatography-mass spectrometry (GC-MS and
LC-MS)-based protocols (30, 31). To evaluate batch effects, a set of 97 samples were
measured in both the 2010 and 2014 batches. There were 384 named metabolites that were
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identified to be present in both batches and these metabolites will be used for this thesis
research.
In the present study, sample-level quality control was performed to remove
individuals with missing values for more than 40% of the measured metabolites (1 sample
was removed from batch 2). After sample-level quality control, metabolomic profiles were
available in 2,479 AAs and 1,553 EAs. Exclusion criteria for metabolites includes: 1) sixthere metabolites were excluded as more than 40% of the samples have missing values or
values below the detection limit (BDL) within each batch; and 2) fifty metabolites were
excluded as the Pearson correlation coefficient (r) between 2010 and 2014 measurements on
the same stored sample (at least 46 out of the 97 pairs) is less than 0.30. After exclusions, this
study was based on an evaluation of 271 named metabolites. Metabolite levels were analyzed
as continuous variables, where missing/BDL values were imputed using random forest
imputation based on the remaining observed measurements (32, 33).

Genotypes
Genotyping was performed with the Illumina HumanExome BeadChip v1.0 (“exome
chip”) querying 247,870 single nucleotide variants (SNVs) at the baseline examination in
11,071 EAs and 2,953 AAs in the ARIC study. The exome chip data was selected rather than
exome or whole genome sequence data that is also available in ARIC because using exome
chip data maximizes the available sample size for this analysis. To improve accurate calling
of rare variants, genotyped data from ARIC along with 10 other studies from the Cohorts for
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Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium were pulled
together for joint calling, details were described elsewhere (34). A total of 8,994 variants
were excluded after laboratory quality control steps, for instance call rate <95%, HardyWeinberg equilibrium test P value (pHWE) < 1×10-6, and poorly clustering variants (34).
SNVs with missing rate >5% were removed from analysis.
Exome chip variant annotation was completed using the Whole Genome Sequencing
Annotation (WGSA) pipeline v055 (35), including dbNSFP v2.9 (36). Functional variants
and genes were determined using ANNOVAR (37) according to the reference genome
GRCh37/hg19 and National Center for Biotechnology Information RefSeq.

Statistical Analysis:
Prior to the analyses, metabolite levels were winsorized (99%) within each batch.
Each metabolite was investigated for its goodness-of-fit to normality. Due to right-skewed
distributions of many metabolite levels, the natural log transformation was applied to most
metabolites prior to analyses. For metabolites that are still not normally distributed, a rank
based inverse normal transformation was used. The transformation methods applied to each
metabolite were provided in Appendix B- Supplemental Table 1.
Two analyses were conducted for each metabolite within each race group: 1) a joint
analysis of genetic main effects and G×E interaction effects and 2) a G×E interaction term
test only. The joint analysis was conducted using rareGE (28), and the interaction term test
was conducted using both rareGE and MiSTi (27, 28). The unit-of-analysis is an annotated
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gene. All annotated coding variants, such as splicing, stop-gain, stop-loss, nonsynonymous,
and indels within the gene were aggregated for the analysis. Additionally, genes with
cumulative minor allele counts ≤ 6 in each race were excluded. Models were adjusted for age
and population substructure using the first three ancestry specific principal components (PCs)
(38), with additional adjustment of estimated glomerular filtration rate (eGFR) and batch
effects for metabolites.
We used AAs as our discovery sample and conducted replication in EAs. Using a
false discovery rate (FDR) to correct for number of genes tested while considering the 271
metabolites, we defined exome-wide significant genes as those with FDR Q≤ 5% in
discovery AAs; these genes were pursued for replication analyses in EAs. Replication was
defined as those genes with FDR Q ≤ 5%, corrected for the number of genes taken forward to
evaluate in EAs. All statistical analyses were conducted in R version 3.4 (R Foundation for
Statistical Computing, Vienna, Austria).

Results
There was a total of 3,540 participants with measured metabolite levels and
genotyped exome chip data in the ARIC study, including 2,012 AAs for discovery and 1,528
EAs for replication. Women comprised more than half of the samples in both race groups
(64.2% in AAs, 54.1% in EAs). In general, the average baseline age of AAs and EAs was
comparable (AAs vs. EAs: 53.0 ± 5.7 vs. 54.6 ± 5.8 years), and AA participants tends to have
slightly higher levels of eGFR (AAs vs. EAs: 104.0 ± 18.3 vs. 91.4 ± 14.6 mL/min/1.73 m²).
42

In AAs, we observed 48 gene-metabolite associations (FDR Q ≤ 5%) harboring rare
and low-frequency variants through the joint analysis using rareGE (Appendix BSupplemental Table 2). Distributions of QQ plots for joint test are shown in Appendix BSupplemental Figure 1. Among them, 38 gene-metabolite associations were available in EAs,
and these were taken forward for replication. In total, 14 gene-metabolite associations were
successfully replicated using the joint test, 3 of which, namely PLA2G7- arachidonate
(20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine, were novel associations
(Table III-1). The interaction term only test using rareGE for NPC2-sex interaction on
leucylserine levels reached nominal significant (p = 3.79×10-04 -- 5.83×10-04 using
random/fix effect interaction models (Table III-1), suggesting that gene-sex interaction
effects contribute to the identified association between NPC2 and leucylserine levels. We
additionally tested the marginal genetic main effect of these 14 gene-metabolite associations
using SKAT test. The marginal genetic main effect of NPC2 on leucylserine levels reached
nominal significance level (p = 1.07×10-03), which also suggesting that both the genetic main
effects and the gene-sex interaction effects contribute to the identified joint effect. Genetic
main effect for the rest of the genes showed similar p-values as results of the joint test (Table
III-1). The rest of the identified gene-metabolite associations were mainly driven by genetic
main effects (rareGE interaction test p > 0.05, Table III-1)
Tests that focused on gene-sex interaction terms alone failed to identify any genes
that passed the FDR corrected significance threshold using either rareGE or MiSTi. Using
FDR Q < 0.2 as a suggestive significance threshold, six gene-metabolite pairs, 4 through
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MiSTi and 3 through rareGE with 1 overlapping, were identified to be suggestive (Appendix
B- Supplemental Table 3-4). Half of the genes had valid interaction test results in EAs, but
the results were not replicated (p > 0.05 in EAs, Appendix B- Supplemental Table 3-4).

Discussion
To our knowledge, this is the first study to evaluate the role of rare and low frequency
variants in gene-sex interactions and joint effects of genetic main and gene-sex interaction on
metabolite levels. In total, we observed and replicated 14 gene-metabolite associations
through the joint test, 3 of which were novel, including PLA2G7- arachidonate (20:4n6),
PTER- N-acetyl-beta-alanine and NPC2- leucylserine. No significant novel loci were
detected via analyzing the gene-sex interactions alone.
Eleven of the 14 identified gene-metabolite pairs, comprised of 6 genes: ALMS1,
ACY1, KLKB1, DMGDH, CCBL1, ACAD8, SLC25A45, and HAL, have been previously
identified through either traditional GWAS or sequence-based genetic association studies that
only considered genetic main effects (5, 6, 12-16). For example, rare loss-of-function
variants in HAL, a gene that encodes histidine ammonia-lyase in the first step of histidine
catabolism, was reported to be associated with increased histidine levels, and further linked
to reduced incidence CHD risk (39). For these 6 known genes influencing metabolite levels,
no evidence of gene-sex interactions were observed, suggesting that these gene-metabolite
associations were not modified by sex.
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Among the novel genes we identified through the joint test, PLA2G7 (Phospholipase
A2 Group VII) was observed to be associated with arachidonic acid (20:4n6) in our data.
Previous studies have reported several mutations in PLA2G7 associated with lipoproteinassociated phospholipase A2 (Lp-PLA2) activity and mass, both positively and negatively
(40-43). A large meta-analysis including 32 prospective studies by Thompson et al (44)
showed that a reduction in Lp-PLA2 activity/mass was associated with reductions in risks of
coronary heart disease and ischemic stroke. In addition, Lp-PLA2 activity has been recently
approved by the FDA for routine clinical use to predict coronary heart disease events
especially for black women (45). Phospholipase A2 (PLA2) catalyzes the hydrolysis of the
sn-2 position of membrane glycerophospholipids to liberate arachidonic acid (46), the
metabolite we observed and known for mediating inflammation (47). Therefore, the
association we observed between PLA2G7 and arachidonic acid (20:4n6) is expected, and
helps understanding the path of genetic variation in PLA2G7 to vascular inflammation and
CVD.
We also observed a novel association between PTER and N-acetyl-beta-alanine levels
using the joint test. Previously GWAS has identified variants near PTER
(phosphotriesterase-related) as a locus for obesity in European populations (48). The
metabolite, N-acetyl-beta-alanine can be broken down to acetate and beta-alanine through
hydrolysis, the latter of which forms carnosine (beta-alanyl-L-histidine), a dipeptide with
anti-inflammatory, antioxidant, anti-glycation, and anti-ischaemic roles on cardiometabolic
risk and disease (49). Current understanding of the protein encoded by PTER was limited to
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hydrolase activity, acting on ester bonds. Our results provide insight into the molecular
function or biological process that PTER may be involved, which may further link to
cardiometabolic diseases.
Out of the three novel gene-metabolite associations we identified and replicated
through the joint test, NPC2- leucylserine also showed a contribution from gene-sex
interaction effects. NPC2 (NPC Intracellular Cholesterol Transporter 2) encodes a protein
that may function in regulating the transport of cholesterol through the late lysosomal system.
In a recent genetic study of the human plasma proteome, common variants in NPC2 gene
have been associated with levels of a blood protein, Cathepsin H (50), which is important in
the overall degradation of lysosomal proteins. The NPC2 and NPC2-sex interaction
associated metabolite in our data, leucylserine, is a dipeptide composed of leucine and serine.
It is an incomplete breakdown product of protein digestion, which can be produced during
lysosomal proteolysis. Although there is a lack of understanding the role of the NPC2-sex
interaction on leucylserine levels, an animal study showed that in the ovary, NPC2 was
restricted to steroidogenic cells that use cholesterol to produce hormones, and reported
female infertility in NPC2 deficient mice (51). It is possible that sex hormones, for example
estradiol, may be further related to lysosomal function (52) and are involved in protein
catabolism that produces leucylserine.
This study has several strengths. We used an emerging statistical approach that jointly
tests the genetic main effect and gene-sex interaction on the human metabolome. Previous
studies have shown that inclusion of G×E interactions may be important for identifying novel
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signals, particularly for rare and low-frequency variants (53). Results in the present study
support this conclusion by showing that novel genes were identified through this joint
approach. Our study focused on the human metabolome, an intermediate phenotype that
known to have larger genetic effects than clinical end points (5, 54), which are suitable to
promote novel gene discoveries in the context of rare variant G×E interactions. Another
strength of the present study is the joint calling of variants in a large pooled sample of studies
conducted in the same laboratory, including the ARIC study. By increasing the sample size
during the calling of variants, the ability to correctly call rare variants is enhanced (55).
We successfully identified novel gene-metabolite associations, but the test that
focuses on gene-sex interactions alone fail to reveal significant results for several reasons.
First, sex may not modify the genetic effects on human metabolome, in other words, genetic
architecture of the serum metabolome is largely consistent between men and women. Second,
the study’s design having discovery in one race group and replication in another may not be
ideal. The discovery sample for this study was AAs, a population with high level of genetic
diversity to promote novel findings (56). However, the replication sample was EAs. Rare
variants aggregated in genes may differ between two races, and ancestry-specific rare
variants may contribute to sex-specific effects on metabolites, which will not be consistent
between races and missed in our analyses. Finally, although we applied newly developed
statistical methods that were known to have improved performance in testing G×E
interactions (27, 28), future studies that focus on rare and low-frequency variants to identify
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novel loci and G×E interactions may require much larger sample sizes than were available in
just the ARIC study.
In conclusion, this study applied emerging statistical approaches to investigate the
role of rare and low-frequency variants in gene-sex interactions on the human metabolome,
and successfully identified 3 novel genes associated with metabolites. Our results show
promise for other larger scale studies analyzing rare variant GxE interactions to reveal novel
biology.

48

References
1.

Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted
ultrahigh performance liquid chromatography/electrospray ionization tandem mass
spectrometry platform for the identification and relative quantification of the smallmolecule complement of biological systems. Analytical chemistry.
2009;81(16):6656-67.

2.

Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics—a review in
human disease diagnosis. Analytica chimica acta. 2010;659(1-2):23-33.

3.

Villas‐Bôas SG, Mas S, Åkesson M, Smedsgaard J, Nielsen J. Mass spectrometry in
metabolome analysis. Mass spectrometry reviews. 2005;24(5):613-46.

4.

Gieger C, Geistlinger L, Altmaier E, De Angelis MH, Kronenberg F, Meitinger T, et
al. Genetics meets metabolomics: a genome-wide association study of metabolite
profiles in human serum. PLoS Genet. 2008;4(11):e1000282.

5.

Shin S-Y, Fauman EB, Petersen A-K, Krumsiek J, Santos R, Huang J, et al. An atlas
of genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543-50.

6.

Suhre K, Shin S-Y, Petersen A-K, Mohney RP, Meredith D, Wägele B, et al. Human
metabolic individuality in biomedical and pharmaceutical research. Nature.
2011;477(7362):10.1038/nature10354.

7.

Krumsiek J, Suhre K, Evans AM, Mitchell MW, Mohney RP, Milburn MV, et al.
Mining the Unknown: A Systems Approach to Metabolite Identification Combining
Genetic and Metabolic Information. PLoS Genetics. 2012;8(10):e1003005.
49

8.

Draisma HHM, Pool R, Kobl M, Jansen R, Petersen A-K, Vaarhorst AAM, et al.
Genome-wide association study identifies novel genetic variants contributing to
variation in blood metabolite levels. Nature communications. 2015;6:7208-.

9.

Ried JS, Shin S-Y, Krumsiek J, Illig T, Theis FJ, Spector TD, et al. Novel genetic
associations with serum level metabolites identified by phenotype set enrichment
analyses. Human Molecular Genetics. 2014;23(21):5847-57.

10.

Rhee EP, Ho JE, Chen M-H, Shen D, Cheng S, Larson MG, et al. A Genome-Wide
Association Study of the Human Metabolome in a Community-Based Cohort. Cell
metabolism. 2013;18(1):130-43.

11.

Rhee EP, Yang Q, Yu B, Liu X, Cheng S, Deik A, et al. An exome array study of the
plasma metabolome. Nature Communications. 2016;7:12360.

12.

Yu B, Li AH, Metcalf GA, Muzny DM, Morrison AC, White S, et al. Loss-offunction variants influence the human serum metabolome. Science Advances.
2016;2(8):e1600800.

13.

Long T, Hicks M, Yu H-C, Biggs WH, Kirkness EF, Menni C, et al. Whole-genome
sequencing identifies common-to-rare variants associated with human blood
metabolites. Nat Genet. 2017;49(4):568-78.

14.

Yu B, de Vries PS, Metcalf GA, Wang Z, Feofanova EV, Liu X, et al. Whole genome
sequence analysis of serum amino acid levels. Genome Biology. 2016;17(1):237.

50

15.

Yu B, Zheng Y, Alexander D, Morrison AC, Coresh J, Boerwinkle E. Genetic
determinants influencing human serum metabolome among African Americans. PLoS
Genet. 2014;10.

16.

Feofanova EV, Yu B, Metcalf GA, Liu X, Muzny D, Below JE, et al. SequenceBased Analysis of Lipid-Related Metabolites in a Multiethnic Study. Genetics.
2018;209(2):607-16.

17.

Menni C, Graham D, Kastenmüller G, Alharbi NHJ, Alsanosi SM, McBride M, et al.
Metabolomic identification of a novel pathway of blood pressure regulation involving
hexadecanedioate. Hypertension. 2015;66(2):422-9.

18.

Fan S, Yeon A, Shahid M, Anger JT, Eilber KS, Fiehn O, et al. Sex-associated
differences in baseline urinary metabolites of healthy adults. Scientific Reports.
2018;8(1):11883.

19.

Rist MJ, Roth A, Frommherz L, Weinert CH, Krüger R, Merz B, et al. Metabolite
patterns predicting sex and age in participants of the Karlsruhe Metabolomics and
Nutrition (KarMeN) study. PLOS ONE. 2017;12(8):e0183228.

20.

Mittelstrass K, Ried JS, Yu Z, Krumsiek J, Gieger C, Prehn C, et al. Discovery of
Sexual Dimorphisms in Metabolic and Genetic Biomarkers. PLOS Genetics.
2011;7(8):e1002215.

21.

Krumsiek J, Mittelstrass K, Do KT, Stückler F, Ried J, Adamski J, et al. Genderspecific pathway differences in the human serum metabolome. Metabolomics.
2015;11(6):1815-33.
51

22.

Gorlov IP, Gorlova OY, Frazier ML, Spitz MR, Amos CI. Evolutionary evidence of
the effect of rare variants on disease etiology. Clinical genetics. 2011;79(3):199-206.

23.

Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al.
Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747-53.

24.

Kraft P, Yen Y-C, Stram DO, Morrison J, Gauderman WJ. Exploiting geneenvironment interaction to detect genetic associations. Human heredity.
2007;63(2):111-9.

25.

Manning AK, LaValley M, Liu C-T, Rice K, An P, Liu Y, et al. Meta-analysis of
gene-environment interaction: joint estimation of SNP and SNP × environment
regression coefficients. Genetic Epidemiology. 2011;35(1):11-8.

26.

Lin X, Lee S, Wu MC, Wang C, Chen H, Li Z, et al. Test for Rare Variants by
Environment Interactions in Sequencing Association Studies. Biometrics.
2016;72(1):156-64.

27.

Su Y-R, Di C-Z, Hsu L. A unified powerful set-based test for sequencing data
analysis of GxE interactions. Biostatistics. 2017;18(1):119-31.

28.

Chen H, Meigs JB, Dupuis J. Incorporating Gene-Environment Interaction in Testing
for Association with Rare Genetic Variants. Human Heredity. 2014;78(2):81-90.

29.

ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) study: design
and objectives. American journal of epidemiology. 1989;129(4):687-702.

52

30.

Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted
ultrahigh performance liquid chromatography/electrospray ionization tandem mass
spectrometry platform for the identification and relative quantification of the smallmolecule complement of biological systems. Anal Chem. 2009;81(16):6656-67.

31.

Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al.
Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced
toxicology in Fischer 344 male rats. Toxicologic pathology. 2009;37(4):521-35.

32.

Stekhoven DJ, Bühlmann P. MissForest—non-parametric missing value imputation
for mixed-type data. Bioinformatics. 2012;28(1):112-8.

33.

Breiman L. Random forests. Machine learning. 2001;45(1):5-32.

34.

Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, et al. Best Practices
and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium. PLoS
ONE. 2013;8(7):e68095.

35.

Liu X, White S, Peng B, Johnson AD, Brody JA, Li AH, et al. WGSA: an annotation
pipeline for human genome sequencing studies. Journal of medical genetics.
2015:jmedgenet-2015-103423.

36.

Liu X, Jian X, Boerwinkle E. dbNSFP v2. 0: a database of human non‐synonymous
SNVs and their functional predictions and annotations. Human mutation.
2013;34(9):E2393-E402.

37.

Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants
from high-throughput sequencing data. Nucleic acids research. 2010;38(16):e164-e.
53

38.

Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal
components analysis corrects for stratification in genome-wide association studies.
Nature Genetics. 2006;38:904.

39.

Yu B, Li AH, Muzny D, Veeraraghavan N, Vries PS, Bis JC, et al. Association of
rare loss-of-function alleles in HAL, serum histidine: levels and incident coronary
heart disease. Circ Cardiovasc Genet. 2015;8.

40.

Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al. Eight genetic
loci associated with variation in lipoprotein-associated phospholipase A2 mass and
activity and coronary heart disease: meta-analysis of genome-wide association studies
from five community-based studies. European heart journal. 2012;33(2):238-51.

41.

Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamin A, et al.
Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham
Heart Study. PLoS Genet. 2010;6(4):e1000928.

42.

Chu AY, Guilianini F, Grallert H, Dupuis J, Ballantyne CM, Barratt BJ, et al.
Genome-wide association study evaluating lipoprotein-associated phospholipase A2
mass and activity at baseline and after rosuvastatin therapy. Circ Cardiovasc Genet.
2012;5(6):676-85.

43.

Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, et al. Pharmacogenetic metaanalysis of baseline risk factors, pharmacodynamic, efficacy and tolerability
endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS
One. 2017;12(7):e0182115.
54

44.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al.
Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and
mortality: collaborative analysis of 32 prospective studies. Elsevier; 2010.

45.

Young K. FDA clears test to help predict coronary heart disease risk NEJM Journal
Watch2014 [cited 2018 11.08]. Available from:
https://www.jwatch.org/fw109648/2014/12/17/fda-clears-test-help-predict-coronaryheart-disease-risk.

46.

Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins & other lipid
mediators. 2002;68-69:3-58.

47.

Pompeia C, Lima T, Curi R. Arachidonic acid cytotoxicity: can arachidonic acid be a
physiological mediator of cell death? Cell biochemistry and function. 2003;21(2):97104.

48.

Meyre D, Delplanque J, Chèvre J-C, Lecoeur C, Lobbens S, Gallina S, et al. Genomewide association study for early-onset and morbid adult obesity identifies three new
risk loci in European populations. Nature Genetics. 2009;41:157.

49.

Baye E, Ukropcova B, Ukropec J, Hipkiss A, Aldini G, de Courten B. Physiological
and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino
Acids. 2016;48(5):1131-49.

50.

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic
atlas of the human plasma proteome. Nature. 2018;558(7708):73-9.

55

51.

Busso D, Oñate-Alvarado MJ, Balboa E, Zanlungo S, Moreno RD. Female infertility
due to anovulation and defective steroidogenesis in NPC2 deficient mice. Molecular
and Cellular Endocrinology. 2010;315(1):299-307.

52.

Totta P, Pesiri V, Marino M, Acconcia F. Lysosomal function is involved in 17βestradiol-induced estrogen receptor α degradation and cell proliferation. PloS one.
2014;9(4):e94880-e.

53.

Sung YJ, Winkler TW, Manning AK, Aschard H, Gudnason V, Harris TB, et al. An
Empirical Comparison of Joint and Stratified Frameworks for Studying G × E
Interactions: Systolic Blood Pressure and Smoking in the CHARGE Gene-Lifestyle
Interactions Working Group. Genetic Epidemiology. 2016;40(5):404-15.

54.

Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, et al.
Association analysis of 6,736 U.K. subjects provides replication and confirms
TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on
individual risk. Diabetes. 2006;55(9):2640-4.

55.

Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, et al. Best Practices
and Joint Calling of the HumanExome BeadChip: The CHARGE Consortium. PLoS
One. 2013;8(7):e68095.

56.

Tishkoff SA, Williams SM. Genetic analysis of African populations: human evolution
and complex disease. Nature Reviews Genetics. 2002;3:611.

56

Table III-1 Genes discovered and replicated through jointly testing the genetic main effects and gene-sex interactions in the ARIC
study
African-Americans
European- Americans
Trait
N-acetyl-1methylhistidine
aminooctanoate
N-acetyl-alanine
N-acetyl-threonine

Gene

Chr nSNP

Main.p

MiSTi.p Fix.int.p Ran.int.p

Joint.p

ALMS1

2

52

ALMS1

2

52

2.65×10-07

7
7

2.38×10-53

0.60

0.33

0.33

3.93×10-08

0.97

0.45

0.46

4.87×10-07

0.04

0.06

4.57×10-36

7.73×10-30

ACY1
ACY1

3
3

3.94×10-16

0.76

0.99

0.04

0.05

0.19
0.14

0.37
0.27

0.98

4.05×10-09

1.05×10-03

0.13

2.16×10-07

0.02

0.38
0.27

4.43×10-52

1.50×10-45

4.32×10-07

12

1.97×10-33

7
9
7

3.22×10-07
6.53×10-23
3.05×10-08

0.66
0.62
0.70

0.65
0.58
0.62

0.67
0.62
0.55

6.19×10-07

3

6.90×10-13

0.27

0.39

8

1.07×10-07

0.50

0.65

0.98
-

HAL

12

11

leucylserine

NPC2

14

4

1.07×10-3

0.47
0.24

0.47
0.25

4.07×10-23 1.55×10-21
2.71×10-05 1.72×10-04

6.95×10-04

0.72

0.77

0.78

1.58×10-03 6.66×10-03

10 2.28×10-02

0.28

0.16

0.14

0.02

0.05
1.95×10-08

3

13

histidine

1.83×10-05

0.55
0.29

6.05×10-05

4

4.23×10-07

2.15×10-03 8.17×10-03

8.01×10-16 6.77×10-10

KLKB1

SLC25A45 11

0.03

3
3

leucylasparagine

deoxycarnitine

0.05

0.01

1.75×10-23

7

arachidonate (20:4n6) PLA2G7 6
indolelactate
CCBL1 9
N-acetyl-betaalanine PTER 10
isobutyrylcarnitine
ACAD8 11

4.21×10-10

37 4.73×10-03

3

0.17

0.45

0.46

ACY1

5

FDR-Q

3.32×10-11

0.46

N-acetyl-glycine

DMGDH

Joint.p

2.85×10-11

2.06×10-08

dimethylglycine

FDR-Q nSNP Main.p MiSTi.p Fix.int.p Ran.int.p

4.52×10-09

37

8

5.13×10-09

0.71

0.62

0.63

2.56×10-09

0.04
5.15×10-23 5.81×10-17
3.07×10-08 0.006

7
4
4

0.12
7.75×10-05
3.28×10-11

0.03
NA
0.09

0.02
0.34
0.10

0.01
0.30
0.09

0.02
0.05
2.70×10-04 1.47×10-03
9.84×10-12 1.87×10-10

0.41

6.98×10-13 3.37×10-07

3

3.08×10-10

0.25

0.19

0.20

2.58×10-10 2.45×10-09

0.66

1.70×10-07

5

2.24×10-03

0.40

0.39

0.45

4.37×10-03

0.98

7.07×10-07

0.05

14

1.14×10-03

0.22

0.17

0.16

8.69×10-04 4.13×10-3

5.83×10-04 3.79×10-04 1.93×10-07

0.02

5

2.79×10-03

0.08

0.03

0.07

6.78×10-03

0.08

0.99

0.02

0.02
0.02

Main.p: p-value of genetic main effect from SKAT test; MiSTi.p: p-value of MiSTi interaction test; Fix.int.p: p-value of rareGE fixed
effect interaction test; Ran.int.p: p-value of rareGE random effect interaction test; Joint.p: p-value of rareGE joint test; FDR-Q: false
discovery rate Q-values of rareGE joint test
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CHAPTER IV.

POWER OF TWO EMERGING METHODS FOR DETECTING

AND CHARACTERIZING GENE×SEX INTERACTION EFFECTS FOR RARE
VARIANT ANALYSES COMPARED TO STANDARD STRATIFIED ANALYSES
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Abstract
Although it is well known that complex diseases are influenced by both genetic and
environmental factors, examples of validated gene by environment (G×E) interactions, especially
for rare variants, are not common in epidemiological studies. One reason can be incomplete
knowledge of the power of statistical methods used to search for rare variant G×E interactions in
a given dataset. Improved understanding of the power of GxE interaction analyses may lead to
better analysis and characterization of G×E interactions. We carried out a simulation study to
investigate the performance of two newly developed methods, rareGE and MiSTi, that extend
well-established common variant approaches in detecting rare variant gene-sex interaction
effects on a quantitative phenotype. Compared with conventional burden tests, rareGE and
MiSTi have superior performance in their power of identifying rare variant gene-sex interactions
under a wide range of scenarios. Simulation results illustrate that an approach that jointly tests
the genetic main effects and gene-sex interactions increases statistical power and has the
potential to uncover novel genetic signals that have not been identified previously. In summary,
use of simulated data for evaluation of the statistical power of emerging methods to detect rare
variant G×E interactions shows an increase in statistical power for these newly introduced
methods and justifies their use in practice.
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Introduction
Traditional genome-wide association studies (GWAS) have successfully identified a
large number of loci associated with complex diseases and quantitative risk factor phenotypes.
However, a large proportion of the heritability of these diseases/traits remains unexplained (1).
Gene-environment (G×E) interactions, defined as different effects of a genotype on disease risk
between differing environmental exposures (2, 3), and rare and low-frequency genetic variants,
defined as variants with minor allele frequency (MAF) ≤5%, may both account for some of the
unexplained heritability of complex disease-related phenotypes (4).
Several large-scale genome-wide G×E studies have successfully identified novel loci
accounting for the modifying effects of environmental exposures such as age, sex, BMI, alcohol
consumption, and smoking status on cardiovascular disease (CVD) and its related intermediate
traits (5-9). Studying G×E interactions involving rare variants may further extend our knowledge
of the genetic architecture of complex traits and improve our understanding of the underlying
mechanisms of common diseases (10-12). However, unlike well-established G×E interaction
tests for common variants (13, 14), methods development for detecting rare variant G×E
interactions is challenging for several reasons. First, considering typical sample sizes of most
published GWAS studies, a single marker test is underpowered for rare and low frequency
variants with MAF ≤5%. Second, conventional burden tests that simply summarize the total
number of variants within a region and fit a model with this burden by environment interaction
term, often result in inflated type 1 error rates and biased estimates when the genes and
environment are not independent (i.e. G×E correlation) (15).
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Recently developed novel approaches for testing rare variant G×E interaction effects (1520) face limitations. Jiao and colleagues (18, 19) treated genetic main effects as fixed effects,
which may suffer from inflated type I error when the variants are rare (21). Lin et al proposed an
interaction Sequence Kernel Association Test (15) that is powerful when both positive and
negative directions of G×E effects exist, yet loses power when the variants in the set have the
same direction of G×E effects. Tzeng et al. (16) assumed comparable magnitude of the variance
component parameters for genetic main effects and G×E interactions, which may not be
powerful if this assumption is not satisfied. Emerging methods have been proposed to overcome
the aforementioned limitations. Su et al. proposed a novel and rigorous framework, Mixed
effects Score Tests for interaction (MiSTi), to derive independent score statistics for fixed effects
and the variance component, which is more powerful to test G×E interaction terms of rare
variants (21). A joint test that allows one to simultaneously test genetic main effects and
interaction effects and requires no assumption about the magnitude of the variance component
parameters for the genetic main effects and G×E interactions was proposed and successfully
implemented by Chen and colleagues in the R package called ‘rareGE’ (22). The former
interaction-only test allows detecting G×E interactions regardless of the genetic main effect,
while the latter joint testing approach aims to detect associated genetic effects allowing for geneenvironment interactions.
Compared to common variant analyses, rare variant analyses often require a larger
sample size to attain comparable power. Interaction analyses also need larger sample sizes in
comparison with main effect analysis (23, 24). Therefore, interaction analyses for rare genetic
variants require extra attention, particularly related to consideration of statistical power in studies
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with a fixed sample size. In this chapter, we compared the performance and power of two
emerging approaches “rareGE” (22) and “MiSTi” (21) with standard stratified analyses followed
by a test of the differences of the effect sizes, “Z test”, (25) in simulation studies using real
genotype data from European-Americans (EAs) in the Atherosclerosis Risk in Communities
(ARIC) study.

Methods- Simulation Studies
“MiSTi” and “rareGE” have been shown to maintain a correct type I error rate under the
null hypothesis (no G×E interactions) (21, 22). I evaluated and compared their power with the “Z
test” for detecting rare variant gene-sex interactions under different scenarios assuming the gene
variants and gene-sex interactions were associated with a quantitative phenotype (metabolite
levels) but with varying effect sizes and directions of effects, as well as the total sample size. I
also investigated the power of the rareGE joint test that allows one to simultaneously test genetic
main effects and interaction effects in the aforementioned scenarios.

Study Sample
The ARIC study is a population-based prospective cohort study of 15,792 adults from
four U.S. communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and
Washington County, MD), which has been described in detail previously (29). ARIC included
both EAs and AAs aged 45-64 at the baseline examination (1987-1989). Participants completed
three additional triennial follow-up examinations, a fifth exam in 2011-2013, and a sixth exam in
2016-2017. There were 11,071 participants with exome chip genotyped data at the baseline
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examination. The ARIC study has been approved by the institutional review boards at each site,
and written informed consent was obtained from all participating individuals.

Simulation Design
Part 1. Detecting gene-sex interaction
To evaluate the performance of the two emerging approaches and the conventional Z test
in detecting gene-sex interaction, I first selected 10 genes having varying number of SNVs and
pattern of linkage disequilibrium from the exome chip data genotyped in 11,071 EAs.
For each gene, the modeled metabolite was generated with 500 replicates from,
Y = 𝛽0 + 𝛽𝐸 𝑠𝑒𝑥 + ∑𝑃𝑝=1 𝛽𝑝𝐺 𝐺𝑝 + ∑𝑃𝑝=1 𝛽𝑝𝐺𝐸 𝐺𝑝 𝑠𝑒𝑥 + 𝜀, where ε ~ N (0, 1) is a normal
error term, β0 and βE was estimated from ARIC’s real data. For example, to generate glycine
levels, the estimated β0 and βE from ARIC’s real data are β0 = 1.4, βE =0.6, and
Glycine= 1.4 + 0.6*sex+∑𝑃𝑝=1 𝛽𝑝𝐺 𝐺𝑝 + ∑𝑃𝑝=1 𝛽𝑝𝐺𝐸 𝐺𝑝 (𝑠𝑒𝑥 − 0.5) + 𝜀
The proportion of causal SNVs was set to 20% for each of the 10 genes. The effect size
of non-causal SNVs was set to be zero. The effect size of the causal genetic main effect 𝛽𝑝𝐺 was
simulated under 2 settings:
Setting 1. Randomly selected causal SNVs 𝛽𝑝𝐺 ~ U(0,1), and 0 otherwise.
Setting 2. 10% randomly selected causal SNVs 𝛽𝑝𝐺 ~ U(0,1), and the betas for the other
10% will be randomly selected causal SNVs 𝛽𝑝𝐺 ~ U(-1,0), and 0 otherwise.
Settings 1 and 2 simulated two extreme cases where genetic main effects favors burden
(all in the same direction) and variance component (50% positive and 50% negative),
respectively.
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For each genetic main effect setting considered, the size of interaction effects was
controlled by a constant c, which varied from 0.5, 1, 1.5 to 2, so that the power estimated under
difference methods was discernible. I simulated 2 scenarios of gene-sex interactions:
Scenario 1. 20% of randomly selected 𝛽𝑝𝐺𝐸 = c, and 0 otherwise
Scenario 2. 10% of randomly selected 𝛽𝑝𝐺𝐸 = 𝑐, and 10% of randomly selected 𝛽𝑝𝐺𝐸 = -c,
and 0 otherwise
Scenario 1 represented a moderate interaction effect scenario with 20% of the variants
having the interaction effect in the same direction. Scenario 2 represented a moderate interaction
effect with 20% variants having the interaction effect in opposite directions. The constant c was
varied from 0.5, 1, 1.5, to 2 to evaluate the size of the interaction effect on power. The empirical
power of each method under each scenario was calculated by comparing the resulting p-value to
a cut-off value declaring statistical significance, α. I then calculated the proportion of times the
null hypothesis was rejected (success rate) over the 500 replicates. I considered two α levels, one
for nominal significance level p < 0.05, the other for exome-wide false discovery rate (FDR) <
5%. Because I simulated metabolite levels based on variants within one gene each time and
expected only one gene to be associated with the simulated phenotype across the exome, the
FDR < 5% is equivalent to a Bonferroni corrected p < 4.95×10-6.

Part 2. Effect of sample size on power
To evaluate the effect of sample size on power, I doubled the exome chip data and then
randomly selected subsets of the doubled genomic dataset to vary sample size from 20,000 down
to 2,000. For this power simulation, I selected two scenarios when causal markers have main
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effects in opposite directions (same as setting 2 of genetic main effects in part 1) and gene-sex
interaction effects in the same direction and opposite directions (same as scenario 1 and 2 of
interaction effects in part 1). To be specific, again using glycine as an example, the dataset was
generated with parameters settings as below
1. Glycine= 1.4 + 0.6*sex+∑𝑃𝑝=1 𝛽𝑝𝐺 𝐺𝑝 + ∑𝑃𝑝=1 𝛽𝑝𝐺𝐸 𝐺𝑝 (𝑠𝑒𝑥 − 0.5) + 𝜀
2. 20% of the SNVs within each gene are causal SNVs
3. 10% randomly selected causal SNVs 𝛽𝑝𝐺 ~ U(0,1), and the betas for the other 10% will be
randomly selected causal SNVs 𝛽𝑝𝐺 ~ U(-1,0), and 0 otherwise
4.
a. 10% of randomly selected 𝛽𝑝𝐺𝐸 = 1, and 10% of randomly selected 𝛽𝑝𝐺𝐸 = -1, and
0 otherwise
b.

20% of randomly selected 𝛽𝑝𝐺𝐸 = 1, and 0 otherwise

Step 3 generated 20% causal variants with genetic main effects in opposite directions.
Step 4a represented a moderate interaction effect with 20% of the variants having the interaction
effects in the opposite directions. 4b represented a moderate interaction effect with 20% variants
having the interaction effects in the same direction. Following the same procedure as in part 1,
the empirical power under different sample sizes was calculated by comparing the resulting pvalue to the significance level α (0.05 or 4.95×10-6) to determine success or failure and then
computing the rate over 500 replicates.
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Results
Part 1. Performance in detecting gene-sex interaction
The ten selected genes with varying number of SNVs and cumulative minor allele counts
(cMAC) are presented in Table IV-1. The LD pattern for each of the selected genes is presented
in supplemental figure 1. Rare and low-frequency variants aggregated in the selected genes are
not in LD or in very low to moderate LD. The highest average LD observed is for the gene
KIAA1551 (average LD < 0.1).
Figure IV-1 shows the average power results across the 10 genes using the three methods
with positive genetic main effects and two scenarios of interaction effects. Empirical power was
calculated at the significance level of 0.05 and 4.95×10-6, respectively. The data shows a clear
trend of increasing power with increasing effect sizes for the interaction effects and highlights
that these two newly developed methods outperform the conventional Z test under each situation
investigated here. Notably, at exome-wide significance, even these newly developed methods for
testing interaction effects are greatly underpowered (less than 50% power) for a sample size of
11,000, while the joint test of genetic main effects and gene-sex interaction effects has a nearly
70% power for the same sample size with a modest genetic main effect we simulated. The data
presented in Figure IV-1 shows that MiSTi is a more powerful test than rareGE when the causal
markers have interaction effects in the same direction. They also suggest that the rareGE random
effect interaction test has the highest power when the causal markers have interaction effects in
opposite directions, which agrees with our prior expectation; the SKAT-type tests are most
powerful when causal markers have interaction effects in opposite directions. Both MiSTi and
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rareGE showed a substantial higher power than the Z test in each scenario as demonstrated in
Figure IV-1 .
We then examine factors that influenced the performance of each methods in each of the
10 genes, including, 1) number of SNVs and cMAC within each gene; 2) effect size of the
interaction effects; 3) causal markers within a gene having gene-sex interaction effects in the
same vs opposite directions; 4) genetic main effects of causal markers in the same vs opposite
directions. The power results are presented at the significance levels of 0.05 and Bonferroni
corrected 4.95×10-6 and the average power across the 10 genes are summarized in Table IV-2
and accompanying Figures. Figure IV-2 shows that power increases with increasing number of
SNVs and cMAC aggregated within each gene. Comparing Figure IV-3 to Figure IV-2 shows
that the power increases with increasing interaction effect size for each gene (Figure IV-3 genesex interaction effect c = 2 vs. Figure IV-2 gene-sex interaction effect c = 1). MiSTi appears to
be slightly more powerful than the rareGE fixed effect interaction test for most genes, which is
consistent with the results observed for the average power across the 10 genes (Figure IV-1 ).
Figure IV-4 shows the power when causal markers within a gene have interaction effects in
opposite directions, and demonstrates that both newly developed interaction test methods are
superior than the Z test when the causal markers have interaction effects in different directions.
Under such a scenario, the rareGE random effect test has the highest power to test interaction
effects for most genes, which again matches our expectation. Compared to Figure 4b, Figure
IV-5 suggests that that the power remains almost the same no matter whether the causal markers
have the same or different directions of main effects except that the Z test was the least powerful
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under the situation that causal markers have different directions of both genetic main effects and
interaction effects.

Part 2. Effect of sample size on power
Figure IV-6 shows the average power results across 10 genes using the three methods
with genetic main effects in opposite directions, and interaction effects in either the same
direction or opposite directions considering sample size varying from 2000, 5000, 10000, 15000
to 20000. Empirical power was calculated at the significance levels of 0.05 and 4.95×10-6,
respectively. Figure IV-6 shows a clear trend of increasing power with increasing sample size
and demonstrates that the two newly developed methods, rareGE and MiSTi consistently
outperforms the conventional Z test, but are still greatly underpowered (40%) to detect an
exome-wide significance G×E interaction with modest effect size 1 in a sample size of 20,000.
Figure 6a and 6b show the power when causal markers have interaction effects in opposite
directions, and supported our results in part 1 that rareGE random effect test has the highest
power to test interaction effects in such scenario, although the difference between the power of
rareGE random effect test and MiSTi is small. Similarly, Figure 6c and 6d again show that
MiSTi is a more powerful test than rareGE when the causal markers have interaction effects in
the same direction regardless of varied sample size. For the rareGE joint test that simultaneously
considers genetic main effects and interaction effects, the sample size required to detect a gene at
nominal significance level with 80% power would be greater than 10,000 using the simulated
effect sizes based on real data. To detect a gene at exome-wide significance level with sufficient
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power, an even larger sample size (> 20,000) will be required for the effect sizes considered
here.

Discussion
In this chapter, we compared three methods, rareGE, MiSTi and a conventional Z test,
and evaluated their power in detecting gene-sex interaction effects as well as jointly testing for
genetic main effects and gene-sex interaction effects. We show that, 1) both rareGE and MiSTi
tests are more powerful than the conventional Z test in detecting gene-sex interaction effects, in
the context of rare genetic variants analysis; 2) rareGE joint test is the most powerful when both
genetic main effect and gene-sex interaction are present, and the power increases with increasing
effect sizes for the interaction effects.
Compared with a conventional Z test of the interaction effects, rareGE and MiSTi tests
have higher power for the simulated situations considered here, especially when causal genetic
markers have different directions of gene by environment interaction effects. When causal
markers have gene by environment interaction effects in the same direction, MiSTi slightly
outperforms rareGE because rareGE is a SKAT-type test and suffers loss of power in such
scenario (15, 22, 26). In contrast, when causal markers have gene by environment interaction
effects in opposite directions, rareGE outperforms MiSTi, because in this scenario the interaction
effect model favors the variance component, which is the scenario that a SKAT-type test have
the greatest power (27). The rareGE joint test that simultaneously tests genetic main effects and
interaction effects is generally more powerful across the simulated scenarios considered here,
suggesting that a joint test is an attractive approach for testing genetic associations allowing for
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G×E interactions when genetic main effects exist (28). Using this joint test, the results show that
we have sufficient power to detect a gene with moderate effect size at nominal significance level
with a sample size of 10000. However, no matter what methods is used, a much larger sample
size is required to detect exome-wide significant genes.
We applied the rareGE and MiSTi approaches from Chapter 3 of this dissertation using
real data compromising 271 measured and named metabolites and exome chip data genotyped in
3,540 African-Americans (AAs) and EAs from the ARIC study. We identified and replicated 14
gene-metabolite pairs through joint test, including 3 novel associations. There was no exomewide significant gene-sex interaction using either rareGE or MiSTi approach. The real data
results are in line with our simulation results for power: these two newly developed methods are
underpowered to detect an exome-wide significance G×E interaction under the sample sizes
available in the ARIC study. We successfully detected a few novel genes associated with
metabolites through the joint test, likely because the genetic main effects on metabolites are
normally much larger than that for disease or disease risk factor levels (29, 30).
The present simulation study has some limitations. We considered only two extreme
situations, causal genetic variants with G×E interaction effects all in the same direction or
completely in opposite directions. In practice, the directions of causal genetic variants with G×E
interaction effects contributing to complex diseases are most likely a mixture of the two
scenarios. Also, in practice, the proportion of causal variants in a gene may not be 20% as we
simulated. In addition, we did not consider multiple genes simultaneously; the quantitative
phenotype was simulated based on effects of genetic variants within one gene. Under a polygenic
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scenario, the power of testing a particular G×E interaction may be affected by other genetic main
effects or interactions.
In conclusion, we have shown in the context of rare genetic variants that utilizing
emerging statistical methods for detecting G×E interactions leads to an increase in power. The
approach of jointly testing the genetic main effects and G×E interactions for rare variants has the
potential to detect novel genes associated with a phenotype of interest. Our simulations justify
their use in practice and provide guidance on sample size needed under various scenarios.
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Table IV-1 Characteristics of the 10 selected genes in European- Americans from the ARIC
exome chip data
Gene
CHR
nSNV
nSNVused
cMAC
SEMG1

20

12

8

275

LIPG

18

12

11

338

NEFM

8

14

13

668

ANKS3

16

20

14

1482

SLC26A4

7

27

21

349

SYCP2

20

29

17

2899

WDR17

4

32

28

1106

KIAA1551

12

42

31

258

CELSR3

3

54

41

845

COL6A3

2

92

77

2111
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Table IV-2 Power of various methods under scenarios with 2 settings of genetic main
effects (setting 1 genetic main effects in the same direction and setting 2 genetic main
effects in opposite directions) and two scenarios of interaction effects (GxE effects in the
same direction and GxE effects in opposite directions), respectively. The significance levels
α are 0.05, and bonferroni corrected 4.95×10-6, respectively. 2a. the size of interaction
effect c=0.5; 2b. the size of interaction effect c=1; 2c. the size of interaction effect c=1.5;
2d. the size of interaction effect c=2.

Table 2a.
Alpha
levels
0.05

4.95×106

Table 2b.
Alpha
levels
0.05

4.95×106

Methods GxE same direction c=0.5

MiSTi
rareGE
Z test
Joint
MiSTi
rareGE
Z test
Joint

Methods
MiSTi
rareGE
Z test
Joint
MiSTi
rareGE
Z test
Joint

Setting 1
0.395
0.396
0.329
0.702
0.158
0.157
0.456
0.077

Setting 2
0.403
0.393
0.347
0.678
0.165
0.164
0.084
0.434

GxE same direction c=1
Setting 1
Setting 2
0.578
0.579
0.558
0.565
0.490
0.498
0.785
0.768
0.332
0.331
0.331
0.329
0.245
0.250
0.569
0.546
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GxE
opposite
direction
c=±0.5
Setting 1
Setting 2
0.355
0.357
0.387
0.384
0.259
0.254
0.682
0.668
0.137
0.137
0.151
0.149
0.038
0.041
0.434
0.427

GxE opposite direction c=±1
Setting 1
Setting 2
0.507
0.513
0.542
0.553
0.365
0.371
0.762
0.759
0.300
0.299
0.320
0.325
0.187
0.186
0.549
0.536

Table 2c.
Alpha
levels
0.05

4.95×106

Table 2d.
Alpha
levels
0.05

4.95×106

Methods

MiSTi
rareGE
Z test
Joint
MiSTi
rareGE
Z test
Joint

Methods
MiSTi
rareGE
Z test
Joint
MiSTi
rareGE
Z test
Joint

GxE same direction
c=1.5
Setting 1
Setting 2
0.693
0.690
0.672
0.667
0.599
0.600
0.838
0.822
0.442
0.447
0.422
0.425
0.336
0.337
0.642
0.629

GxE
opposite
direction
c=±1.5
Setting 1
Setting 2
0.604
0.618
0.650
0.657
0.433
0.442
0.819
0.814
0.392
0.396
0.410
0.412
0.249
0.250
0.623
0.618

GxE same direction c=2
Setting 1
Setting 2
0.753
0.756
0.742
0.732
0.673
0.678
0.862
0.854
0.525
0.531
0.487
0.498
0.397
0.405
0.701
0.680

GxE opposite direction c=±2
Setting 1
Setting 2
0.677
0.689
0.719
0.727
0.505
0.494
0.851
0.850
0.454
0.464
0.483
0.492
0.297
0.286
0.678
0.674
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Figure IV-1 Power of three methods with positive genetic main effects and two scenarios of
interaction effects (1a & 1c. GxE in the same direction; 1b & 1d. GxE in
opposite directions). The significance threshold for 1a & 1b is Bonferroni
corrected (4.95×10-6), for 1c & 1d is 0.05.

GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05
significance threshold; MiSTi.bonf/MiSTi05: the power of MiSTi interaction test under
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni
corrected/0.05 significance threshold
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Figure IV-2 Power of three methods with genetic main effects in both directions and genesex interaction effects in the same direction (c=1). The significance threshold for
2a is 0.05 for 2b is Bonferroni corrected 4.95×10-6.

Figure 2a.

Figure 2b.

GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under
Bonferroni corrected/0.05 significance threshold; GEfix.bonf/GEfix05: the power of rareGE
fix effect interaction test under Bonferroni corrected/0.05 significance threshold;
Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni corrected/0.05
significance threshold; cMAC: cumulative minor allele counts
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Figure IV-3 Power of three methods with genetic main effects in both directions and genesex interaction effects in the same direction (c= 2). The significance threshold
for 3a is 0.05 for 3b is Bonferroni corrected 4.95×10-6.

Figure 3a.

Figure 3b.

GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under
Bonferroni corrected/0.05 significance threshold; GEfix.bonf/GEfix05: the power of rareGE
fix effect interaction test under Bonferroni corrected/0.05 significance threshold;
Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni corrected/0.05
significance threshold; cMAC: cumulative minor allele counts
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Figure IV-4 Power of three methods with genetic main effects and gene-sex interaction
effects in different directions (c = ±2). The significance threshold for 4a is 0.05
for 4b is Bonferroni corrected 4.95×10-6.
Figure 4a.

Figure 4b.

GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni
corrected/0.05 significance threshold; cMAC: cumulative minor allele counts
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Figure IV-5 Power of three methods with genetic main effects in the same direction and
gene-sex interaction effects in different directions (c = ±2). The significance
threshold is Bonferroni corrected 4.95×10-6.

GEjoint.bonf: the power of rareGE joint test under Bonferroni corrected significance
threshold; Fisher.bonf: the power of MiSTi interaction test under Bonferroni corrected
significance threshold; GErandom.bonf: the power of rareGE random effect interaction test
under Bonferroni corrected significance threshold; Ztest.bonf: the power of the conventional
Z test under Bonferroni corrected significance threshold; cMAC: cumulative minor allele
counts
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Figure IV-6 Power comparisons of three methods with genetic main effects in opposite
directions and two scenarios of interaction effects (6a & 6b. GxE in opposite
directions c = ±1; 6c & 6d. GxE in the same direction c = 1) under different
significance thresholds and varied sample size.
6a. α= 0.05

6b. α= 4.95×10-6

6c. α= 0.05

6d. α= 4.95×10-6

GEjoint.bonf/GEjoint05: the power of rareGE joint test under Bonferroni corrected/0.05
significance threshold; Fisher.bonf/Fisher05: the power of MiSTi interaction test under
Bonferroni corrected/0.05 significance threshold; GErandom.bonf/GErandom05: the power
of rareGE random effect interaction test under Bonferroni corrected/0.05 significance
threshold; Ztest.bonf/Ztest05: the power of the conventional Z test under Bonferroni
corrected/0.05 significance threshold; cMAC: cumulative minor allele counts
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CHAPTER V.

SYNTHESIS

This dissertation utilized metabolomic profiling and exome chip data to evaluate sexspecific genetic effects and gene-sex interactions on the serum metabolome with a particular
focus on rare and low-frequency (minor allele frequency ≤ 5%) genetic variants (Chapter 23). The study participants included both African-Americans (AAs) and European-Americans
(EAs) belonging to the large population-based Atherosclerosis Risk in Communities (ARIC)
study. A simulation study (Chapter 4) was conducted to evaluate the power of three different
methods for testing rare variant gene-sex interactions, and the results of this simulation study
served as a justification of the analyses performed in Chapters 2 and 3. Overall, several
genetic variants, either common genetic variants or rare and low-frequency variants
aggregated within a gene, were identified to be significantly associated with metabolite
levels. These findings underscore challenges and opportunities for identifying gene by
environment (G×E) interactions and novel genetic loci by taking into account environmental
factors and may lead to better understanding of disease.

Summary of results
In Chapter 2, we performed a sex-stratified exome-wide association study for 271
GC-MS/LC-MS measured named metabolites in ARIC AAs, and pursued replication in an
independent sample of ARIC EA men and women. . A novel common variant, rs11555566,
in the ADA gene was associated with N1-methyladenosine levels, which was successfully
identified and replicated in both men and women in both race groups. The results suggested a
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larger effect of rs11555566 in men (estimated effect 0.18-0.22) as compared to women
(estimated effect 0.14-0.17), but the difference was not statistically significant. In addition,
we observed variants in 6 genes using common single variant tests or burden tests suggesting
differing genetic effects on metabolite levels through testing for difference of the effect size
estimates in sex-stratified results. However, the difference between the sexes was not shown
to be consistent in an independent sample of ARIC EAs. This study suggests that sex-specific
genetic effects of metabolites may exist, but the lack of consistency in testing sex differences
of the genetic effects between discovery and replication samples underscores that future
studies should consider sex-specific effects with improved (i.e. more powerful in the setting
of rare variants) statistical methods and tools. Accordingly, we conducted an exome-wide
gene-sex interaction study using emerging statistical methods, rareGE and MiSTi in Chapter
3. To our knowledge, this is the first large-scale study to evaluate the role of rare and low
frequency variants in gene-sex interactions and joint effects of genetic main and gene-sex
interaction on metabolite levels. In total, we observed and replicated 14 gene-metabolite
associations through the joint test, 3 of which were novel, including PLA2G7- arachidonate
(20:4n6), PTER- N-acetyl-beta-alanine and NPC2- leucylserine. No significant novel loci
were detected via analyzing gene-sex interactions alone. Although we applied newly
developed statistical methods that were known to have improved performance in testing G×E
interactions (48, 49), studies that focus on rare and low-frequency variants to identify novel
loci and G×E interactions may require much larger sample size than that available in this
dissertation research.
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In Chapter 4, we compared three methods, rareGE, MiSTi and the conventional Z
test, and evaluated their power in detecting gene-sex interaction effects as well as jointly
testing for genetic main effects and gene-sex interaction effects. We illustrate that: 1)
compared with the conventional Z test, rareGE and MiSTi have superior performance in their
power of identifying rare variant gene-sex interactions under a wide range of scenarios, and
2) the rareGE joint test is most powerful when both genetic main effect and gene-sex
interaction are present, and the power increases with increasing effect sizes for the interaction
effects, which demonstrates the potential to uncover novel genetic signals that have not been
identified previously.
Previous studies of the association between genetic variants and metabolite levels
rarely considered sex as a potential effect modifier. These studies identified numerous
genetic loci associated with one or multiple metabolite levels (73-85). In contrast to previous
efforts, this dissertation is devoted to evaluating possible sex-specific common genetic
effects and the role of rare and low-frequency genetic variants on the serum metabolome
while taking into account sex effects. My results identified several novel genetic variants
influencing the human metabolome, and the rigor of these findings was established through
significant discovery in AAs and successful replication in EAs from the ARIC study. Sexspecific genetic effects and gene-sex interaction effects have been shown to contribute to the
observed novel gene-metabolite associations. Our results demonstrate increased power from
using emerging statistical methods for detecting gene-sex interactions and show promise for
other larger scale studies analyzing rare variant GxE interactions to reveal novel biology.
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Strength and Limitations
This dissertation takes full advantage of available data in the large multi-ethnic ARIC
study to explore sex-specific genetic effects and gene-sex interactions with a focus on rare
and low-frequency genetic variants on the metabolome using multiple statistical approaches.
The genetic variants of the exome chip data in the ARIC study were jointly called in a larger
pooled sample of studies conducted in the same laboratory, including the ARIC study. By
increasing the sample size during the calling of variants, the ability to correctly call rare
variants is enhanced (94), which facilitate the identification of novel genetic variants. In
addition to the conventional Z test that tests the difference of the effect size estimates from
sex-stratified analyses, we applied emerging statistical approaches for rare variant gene-sex
interactions and jointly tested for genetic main effects and gene-sex interactions on the
human metabolome. Previous studies have shown that inclusion of G×E interactions is
important in terms of identifying novel signals, particularly for rare and low-frequency
variants (38). Results in the present study supported this conclusion by showing that novel
genes were identified through the joint approach.
Limitations of the present dissertation warrant consideration. There are several
reasons that may have caused lack of consistency in testing sex differences of the genetic
effects between AAs and EAs. First, it may be that sex does not modify the genetic effects on
the human metabolome. In other words, the genetic architecture of the serum metabolome is
consistent between men and women. Second, the study design involved discovery in one race
group and replication in another and this may not be ideal. The discovery sample for this
study was AAs, a population with high level of genetic diversity to promote novel findings
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(95). However, the replication sample was EAs. Rare variants aggregated in genes may differ
between the two race groups, and ancestry-specific rare variants may contribute to sexspecific effects on metabolites, which will not be consistent between races and missed in our
analyses. Further studies with discovery and replication samples in an ancestry-specific
manner followed by a trans-ancestry meta-analysis will have the advantage of discovering
ancestry-specific rare and low-frequency genetic variants and provide evidence of transancestry loci. Finally, we established that there was likely lack of statistical power to detect
exome-wide rare and low-frequency genetic variant gene-sex interactions in our studies.
Through simulation studies and application in real data, we demonstrated that both sexstratified analyses followed by a Z test testing for difference of the effect size estimates and
current statistical methods in detecting G×E interaction effects were not powerful enough to
detect small to moderate sex difference in genetic effects on the metabolome. Improved
statistical methods and tools with sufficient power and flexibility for testing G×E interactions
are warranted, as well as collaborations across different studies to increase sample size.

Future Directions
The results described above need follow-up studies to better understand underlying
biological processes giving rise to the observed associations and to establish potential links to
disease. Follow-up investigations, such as experimental animal studies, of the genes
identified in the context of interactions with sex or sex-stratified analyses are likely to
provide new insights into the understanding of gene functions and biochemical changes in
men and women. Researchers using genetically modified mice have revealed significant sex
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differences in the development of cardiovascular phenotypes. In many of the models, cardiac
pathological phenotypes were developed in male, but not in female mice as summarized by
Du et al (96). For example, genetic deletion of the peroxisome proliferator-activated receptor
alpha (PPARalpha), a gene involved in cellular lipid utilization, caused cardiac lipid
accumulation, hypoglycemia and death in all male, but only 25% of female mice (97). In
another study, the generated transgenic HDAC5S/A mice overexpressed histone deacetylase
(HDAC) in cardiomyocytes which caused death in male but not in female mice (98).
The genetic markers identified in this dissertation may be used in future studies for
association with disease risk. Previous studies have identified different genetic variants
influencing CVD risk in a sex-specific manner (12, 13, 99, 100). Using identified genetic
factors to construct genetic risk scores has been demonstrated to provide powerful and robust
CVD risk prediction beyond traditional risk factors (101-103). Given these findings,
improved genetic risk profile from sex-specific genetic markers is expected to further
facilitate disease risk prediction.
Metabolomic profiles provide significant insights into biological and
pathophysiological pathways that may be altered during the development and progression of
diseases. However, metabolomic profiling performed from serum may not inform us about
organ-specific pathophysiological processes. For complex diseases such as CVD, molecular
changes occur within the large artery wall or liver may be more informative compared to that
provided by serum. Future metabolomic studies at the organ level may supplement the
measurements of changes in metabolites in serum samples and shape our understanding of
metabolism. On the other hand, a recent study of metabolomic signatures of Alzheimer
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disease (AD) using both brain tissue and blood samples has showed a metabolite class,
sphingolipids that were consistently associated with severity of AD pathology in brain and
AD progression across prodromal and preclinical stages in blood.
During the course of this dissertation, I witnessed two changes to the field of human
genetics First, the transition from GWAS to whole genome sequencing studies. Second, the
introduction of large sample sizes in a single study, such as the Million Veteran Program
(104) and the United Kingdom Biobank (105). These changes offer both opportunities and
challenges to researchers doing genetic analysis. Appropriate analytical approaches are a
continued concern in genetic studies of complex disease. There are multiple challenges, for
examples: how to identify causal genetic variants beyond associations; how to appropriately
and informatively incorporate environmental factors; and how to improve the computational
speed to satisfy the need of handling big data. Utilizing metabolomic data requires additional
analytical techniques to properly account for highly correlated metabolite levels. Developing
novel statistical methods such as machine learning approaches for high dimensional data will
benefit future studies to advance precision medicine through integrating multi-omics data.
Most genetic studies of metabolomics focus on genetic main effects. In this
dissertation, the analyses were extended to G×E interactions. However, only interactions with
sex were tested. This was because sexual dimorphism in metabolites has been previously
observed (87, 106), sex is easy to measure, and a balanced division between sexes may lead
to greater statistical power to discover novel loci. Work on rare variants and interactions with
other environmental exposures (e.g., alcohol and smoking) should be done to improve
understanding and uncover additional genes associated with metabolite levels, refine known
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disease loci, or reveal the underlying biology mechanism influenced by both genetic variants
and environmental factors. Because of limited statistical power, we have shown that most
interactions of rare and low-frequency genetic variants with environment factors cannot be
identified or replicated on a genome-wide scale. One way to ease this problem is to restrict to
the metabolites that were previously linked to genetic variants and environment factors,
which will reduce the multiple-testing burden for analyses. Another way is to pool or metaanalyze metabolomic and genomic measurements from multiple studies together to have a
much larger number of individuals than represented here. It is clear that G×E interaction
studies would have an increased power by increasing the size of the discovery sample (107,
108).

Conclusions
This dissertation work suggests new evidence about sex-specific genetic influences
on the human metabolome and reports novel genetic variants that were not previously
identified when gene-sex interaction effects were omitted in previous studies. Additionally,
this dissertation provides insights into the power and desired sample size in conducting rare
variant G×E interaction studies under various scenarios, which facilitate the understanding of
current G×E interaction results and show promise for future large-scale studies utilizing G×E
interactions to investigate the genetic and environmental factors of disease etiology.
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APPENDICES
Appendix A. supplemental materials for Chapter 2
Supplemental Table 1. List of 271 metabolites and transformation methods applied
Metabolites

Super_Pathway

Sub_Pathway

Platform

Transformation

alanine
asparagine
aspartate
N-acetylalanine
creatine
creatinine
glutamate
pyroglutamine
5-oxoproline
betaine
dimethylglycine
glycine
N-acetylglycine
N-acetylthreonine
serine
threonine
4-guanidinobutanoate
3-methylhistidine
histidine
N-acetyl-1-methylhistidine
trans-urocanate
2-methylbutyrylcarnitine (C5)
3-hydroxyisobutyrate
3-methyl-2-oxovalerate
alpha-hydroxyisovalerate
beta-hydroxyisovalerate
beta-hydroxyisovaleroylcarnitine
isobutyrylcarnitine
isoleucine
isovalerate
isovalerylcarnitine
leucine

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Creatine Metabolism
Creatine Metabolism
Glutamate Metabolism
Glutamate Metabolism
Glutathione Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Guanidino and Acetamido Metabolism
Histidine Metabolism
Histidine Metabolism
Histidine Metabolism
Histidine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism

LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos

rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
not transformed
not transformed
natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
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tiglyl carnitine
valine
glutarate (pentanedioate)
glutarylcarnitine (C5)
lysine
N6-acetyllysine
pipecolate

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

2-aminobutyrate

Amino Acid

2-hydroxybutyrate (AHB)

Amino Acid

methionine sulfoxide

Amino Acid

S-methylcysteine
3-(4-hydroxyphenyl)lactate
3-methoxytyrosine
3-phenylpropionate (hydrocinnamate)
N-acetylphenylalanine
o-cresol sulfate
p-cresol sulfate
phenol sulfate
phenylacetate
phenylacetylglutamine
phenylalanine
phenyllactate (PLA)
tyrosine
acisoga
3-indoxyl sulfate
anthranilate
indoleacetate
indolelactate
indolepropionate
kynurenine
serotonin (5HT)
tryptophan
tryptophan betaine
arginine
citrulline

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Polyamine Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
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LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Pos
LC/MS Polar
LC/MS Pos
LC/MS Pos

natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

LC/MS Pos

rank based inverse normal

GC/MS

natural log

LC/MS Polar

rank based inverse normal

LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log

homocitrulline
N-methylproline
ornithine
pro-hydroxy-pro
proline
trans-4-hydroxyproline
urea
erythronate
glucuronate
trehalose
mannitol
mannose

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Carbohydrate
Carbohydrate
Carbohydrate
Carbohydrate
Carbohydrate

1,5-anhydroglucitol (1,5-AG)

Carbohydrate

glucose

Carbohydrate

glycerate

Carbohydrate

lactate
arabinose
threitol
arabonate
threonate
bilirubin (E,E)
N1-Methyl-2-pyridone-5-carboxamide
pantothenate
alpha-tocopherol
gamma-tocopherol
pyridoxate
phosphate
citrate
malate
succinate
succinylcarnitine
carnitine
deoxycarnitine
5-HETE

Carbohydrate
Carbohydrate
Carbohydrate
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Energy
Energy
Energy
Energy
Energy
Lipid
Lipid
Lipid

Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Aminosugar Metabolism
Aminosugar Metabolism
Disaccharides and Oligosaccharides
Fructose, Mannose and Galactose Metabolism
Fructose, Mannose and Galactose Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Pentose Metabolism
Pentose Metabolism
Ascorbate and Aldarate Metabolism
Ascorbate and Aldarate Metabolism
Hemoglobin and Porphyrin Metabolism
Nicotinate and Nicotinamide Metabolism
Pantothenate and CoA Metabolism
Tocopherol Metabolism
Tocopherol Metabolism
Vitamin B6 Metabolism
Oxidative Phosphorylation
TCA Cycle
TCA Cycle
TCA Cycle
TCA Cycle
Carnitine Metabolism
Carnitine Metabolism
Eicosanoid
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LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Pos
LC/MS Polar
LC/MS Polar
GC/MS
GC/MS
LC/MS Polar

natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal

LC/MS Neg

rank based inverse normal

LC/MS Polar

rank based inverse normal

LC/MS Polar

rank based inverse normal

LC/MS Neg
GC/MS
GC/MS
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Pos
LC/MS Pos
GC/MS
GC/MS
LC/MS Neg
GC/MS
GC/MS
LC/MS Neg
LC/MS Polar
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg

natural log
rank based inverse normal
natural log
rank based inverse normal
not transformed
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal

propionylcarnitine
acetylcarnitine
cis-4-decenoyl carnitine
decanoylcarnitine
hexanoylcarnitine
hydroxybutyrylcarnitine
laurylcarnitine
octanoylcarnitine
oleoylcarnitine
palmitoylcarnitine
stearoylcarnitine
2-aminoheptanoate
2-aminooctanoate
2-hydroxyglutarate
3-carboxy-4-methyl-5-propyl-2furanpropanoate (CMPF)
adipate
azelate (nonanedioate)
dodecanedioate
eicosanodioate
hexadecanedioate
octadecanedioate
sebacate (decanedioate)
suberate (octanedioate)
tetradecanedioate
undecanedioate
13-HODE + 9-HODE
2-hydroxypalmitate
2-hydroxystearate
glycerol
glycerol 3-phosphate (G3P)
inositol 1-phosphate (I1P)
myo-inositol
scyllo-inositol
3-hydroxybutyrate (BHBA)
10-heptadecenoate (17:1n7)
10-nonadecenoate (19:1n9)
eicosenoate (20:1n9 or 11)

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Fatty Acid Metabolism (also BCAA
Metabolism)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid, Amino
Fatty Acid, Amino
Fatty Acid, Dicarboxylate

LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
GC/MS

rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
natural log
natural log
natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Glycerolipid Metabolism
Glycerolipid Metabolism
Inositol Metabolism
Inositol Metabolism
Inositol Metabolism
Ketone Bodies
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid

LC/MS Neg
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
GC/MS
LC/MS Polar
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg

rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
natural log
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margarate (17:0)
myristate (14:0)
myristoleate (14:1n5)
nonadecanoate (19:0)
oleate (18:1n9)
palmitate (16:0)
palmitoleate (16:1n7)
stearate (18:0)
1-arachidonoylglycerophosphocholine
(20:4n6)
1arachidonoylglycerophosphoethanolamine
1-arachidonoylglycerophosphoinositol
1-docosahexaenoylglycerophosphocholine
(22:6n3)
1docosahexaenoylglycerophosphoethanolami
ne
1-docosapentaenoylglycerophosphocholine
(22:5n3)
1-linoleoylglycerophosphoethanolamine
1-oleoylglycerophosphocholine (18:1)
1-palmitoleoylglycerophosphocholine
(16:1)
1-palmitoylglycerophosphoinositol
1-palmitoylplasmenylethanolamine
1-stearoylglycerophosphoethanolamine
2-arachidonoylglycerophosphocholine
2-linoleoylglycerophosphoethanolamine
2-myristoylglycerophosphocholine
5-dodecenoate (12:1n7)
caprate (10:0)
caproate (6:0)
heptanoate (7:0)
laurate (12:0)
pelargonate (9:0)
1-oleoylglycerol (1-monoolein)
1-stearoylglycerol (1-monostearin)
choline

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid

LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

natural log
natural log
natural log
rank based inverse normal
not transformed
not transformed
natural log
rank based inverse normal

Lipid

Lysolipid

LC/MS Pos

rank based inverse normal

Lipid
Lipid

Lysolipid
Lysolipid

LC/MS Neg
LC/MS Neg

natural log
natural log

Lipid

Lysolipid

LC/MS Pos

natural log

Lipid

Lysolipid

LC/MS Neg

rank based inverse normal

Lipid
Lipid
Lipid

Lysolipid
Lysolipid
Lysolipid

LC/MS Pos
LC/MS Neg
LC/MS Pos

natural log
natural log
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Monoacylglycerol
Monoacylglycerol
Phospholipid Metabolism

LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
LC/MS Pos

natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
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glycerophosphorylcholine (GPC)
adrenate (22:4n6)
arachidonate (20:4n6)
dihomo-linoleate (20:2n6)
dihomo-linolenate (20:3n3 or n6)
docosahexaenoate (DHA; 22:6n3)
docosapentaenoate (n3 DPA; 22:5n3)
docosapentaenoate (n6 DPA; 22:5n6)
eicosapentaenoate (EPA; 20:5n3)
linoleate (18:2n6)
linolenate [alpha or gamma; (18:3n3 or 6)]
stearidonate (18:4n3)
glycochenodeoxycholate
glycocholate
taurochenodeoxycholate
glycocholenate sulfate
glycodeoxycholate
glycolithocholate sulfate
glycoursodeoxycholate
taurocholenate sulfate
taurolithocholate 3-sulfate
21-hydroxypregnenolone disulfate
4-androsten-3beta,17beta-diol disulfate (1)
4-androsten-3beta,17beta-diol disulfate (2)
5alpha-androstan-3beta,17beta-diol
disulfate
5alpha-pregnan-3beta,20alpha-diol disulfate
androsterone sulfate
cortisol
cortisone
dehydroisoandrosterone sulfate (DHEA-S)
epiandrosterone sulfate
pregn steroid monosulfate
pregnen-diol disulfate
7-alpha-hydroxy-3-oxo-4-cholestenoate (7Hoca)
cholesterol

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Phospholipid Metabolism
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Primary Bile Acid Metabolism
Primary Bile Acid Metabolism
Primary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Steroid
Steroid
Steroid

LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid

LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log

Lipid
Lipid

LC/MS Neg
GC/MS

rank based inverse normal
rank based inverse normal

hypoxanthine

Nucleotide

Sterol
Sterol
Purine Metabolism, (Hypo)Xanthine/Inosine
containing

LC/MS Neg

rank based inverse normal
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urate

Nucleotide

xanthine
N1-methyladenosine
guanosine
5-methyluridine (ribothymidine)
N-acetyl-beta-alanine
pseudouridine
uridine
alanylleucine
arginylleucine
arginylphenylalanine
glycylleucine
glycylphenylalanine
glycylvaline
histidylleucine
leucylalanine
leucylasparagine
leucylglycine
leucylleucine
leucylserine
phenylalanylglutamate
phenylalanylleucine
phenylalanylphenylalanine
phenylalanylserine
pyroglutamylglycine
serylleucine
N-acetylcarnosine
DSGEGDFXAEGGGVR
gamma-glutamylalanine
gamma-glutamylglutamate
gamma-glutamylisoleucine
gamma-glutamylleucine
gamma-glutamylphenylalanine
gamma-glutamylthreonine
gamma-glutamyltyrosine
gamma-glutamylvaline
HWESASLLR

Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide

Purine Metabolism, (Hypo)Xanthine/Inosine
containing
Purine Metabolism, (Hypo)Xanthine/Inosine
containing
Purine Metabolism, Adenine containing
Purine Metabolism, Guanine containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide Derivative
Fibrinogen Cleavage Peptide
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Polypeptide
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LC/MS Neg

rank based inverse normal

LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

2-hydroxyhippurate (salicylurate)
3-methyl catechol sulfate (1)
4-hydroxyhippurate
4-methylcatechol sulfate
4-vinylphenol sulfate
catechol sulfate
hippurate
methyl-4-hydroxybenzoate sulfate
O-methylcatechol sulfate
propyl 4-hydroxybenzoate sulfate
1,2-propanediol
2-hydroxyisobutyrate
3-hydroxypyridine sulfate
O-sulfo-L-tyrosine
salicylate
erythritol
gluconate
homostachydrine
piperine
stachydrine
thymol sulfate
1,7-dimethylurate
1-methylurate
5-acetylamino-6-amino-3-methyluracil
caffeine
paraxanthine
theobromine
theophylline

Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics

Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Chemical
Chemical
Chemical
Chemical
Drug
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
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LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
GC/MS
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
LC/MS Polar
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

Supplemental Table 2. Female common variants
traits

Name

Gene

acisoga

rs2294757

VNN1

maf.EA
0.38

beta.EA
-0.21

se.EA
0.03

p.EA
3.18E-15

5.72E-15

0.16

-0.17

0.03

9.33E-11

1.85E-05

alanylleucine

rs3733402

KLKB1

0.49

-0.24

0.03

1.82E-13

3.12E-13

0.25

-0.12

0.02

3.23E-07

3.13E-02

2-aminooctanoate

rs3813227

ALMS1

0.26

-0.32

0.03

2.48E-25

6.87E-25

0.24

-0.20

0.03

2.21E-13

6.27E-08

2-aminooctanoate

rs6546837

ALMS1

0.26

-0.33

0.03

4.25E-26

1.27E-25

0.24

-0.20

0.03

2.21E-13

6.27E-08

2-aminooctanoate

rs6546838

ALMS1

0.26

-0.33

0.03

6.34E-27

2.85E-26

0.25

-0.20

0.03

2.57E-14

8.51E-09

2-aminooctanoate

rs6546839

ALMS1

0.26

-0.33

0.03

1.38E-26

5.54E-26

0.24

-0.20

0.03

3.44E-13

8.80E-08

2-aminooctanoate

rs2056486

ALMS1

0.25

-0.33

0.03

2.48E-26

8.94E-26

0.25

-0.20

0.03

2.40E-14

8.51E-09

2-aminooctanoate

rs10193972

ALMS1

0.25

-0.33

0.03

3.19E-26

1.04E-25

0.25

-0.20

0.03

1.92E-14

7.61E-09

2-aminooctanoate

rs1052161

ALMS1

0.39

-0.23

0.03

1.21E-16

2.42E-16

0.33

-0.24

0.02

6.79E-23

2.70E-16

arginine

rs3733402

KLKB1

0.49

-0.06

0.01

2.73E-10

4.10E-10

0.25

-0.07

0.01

1.03E-07

1.24E-02

arginylphenylalanine

rs3733402

KLKB1

0.49

-0.17

0.03

1.81E-09

2.61E-09

0.25

-0.13

0.02

8.45E-09

1.20E-03

dimethylglycine

rs1805073

DMGDH

0.28

-0.07

0.03

0.007489

0.008987

0.48

-0.09

0.02

1.74E-07

1.87E-02

gamma-glutamylisoleucine

rs11107

FBXO7

0.37

-0.06

0.02

0.009588

0.011134

0.39

0.09

0.02

2.79E-07

2.84E-02

histidylleucine

rs3733402

KLKB1

0.49

-0.31

0.03

7.84E-20

1.66E-19

0.25

-0.17

0.02

3.55E-13

8.80E-08

leucylalanine

rs3733402

KLKB1

0.49

-0.17

0.03

5.77E-12

9.02E-12

0.25

-0.19

0.02

2.55E-15

1.12E-09

leucylalanine

rs4253301

KLKB1

0.13

-0.14

0.04

0.000245

0.000327

0.06

-0.22

0.04

9.78E-08

1.21E-02

leucylasparagine

rs3733402

KLKB1

0.49

-0.30

0.04

2.88E-12

4.72E-12

0.25

-0.21

0.03

3.39E-10

6.11E-05

leucylglycine

rs3733402

KLKB1

0.49

-0.26

0.03

6.54E-16

1.24E-15

0.25

-0.20

0.03

1.91E-12

4.21E-07

mannose

rs1260326

GCKR

0.42

-0.13

0.01

2.30E-21

5.51E-21

0.13

-0.12

0.02

1.18E-08

1.61E-03

N1-methyladenosine

rs11555566

ADA

0.07

0.17

0.04

7.55E-05

0.000105

0.08

0.14

0.02

2.24E-11

4.67E-06

N-acetyl-1-methylhistidine

rs3813227

ALMS1

0.26

0.44

0.03

5.11E-49

3.07E-48

0.24

0.18

0.02

1.95E-20

1.11E-14

N-acetyl-1-methylhistidine

rs2037814

ALMS1

0.13

-0.10

0.04

0.006627

0.008227

0.11

-0.15

0.03

3.30E-09

5.04E-04

N-acetyl-1-methylhistidine

rs6546837

ALMS1

0.26

0.44

0.03

5.12E-50

6.14E-49

0.24

0.18

0.02

1.95E-20

1.11E-14

N-acetyl-1-methylhistidine

rs6546838

ALMS1

0.26

0.44

0.03

2.43E-49

1.75E-48

0.25

0.18

0.02

4.07E-21

7.65E-15
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pval.BH.EA

maf.AA

beta.AA

se.AA

p.AA

pval.BH.AA

N-acetyl-1-methylhistidine

rs6546839

ALMS1

0.26

0.44

0.03

2.08E-49

1.75E-48

0.24

0.18

0.02

9.64E-21

7.65E-15

N-acetyl-1-methylhistidine

rs3820700

ALMS1

0.14

-0.12

0.04

0.001535

0.001973

0.11

-0.16

0.03

1.43E-09

2.27E-04

N-acetyl-1-methylhistidine

rs2056486

ALMS1

0.25

0.44

0.03

3.84E-50

6.14E-49

0.25

0.18

0.02

8.27E-21

7.65E-15

N-acetyl-1-methylhistidine

rs10193972

ALMS1

0.25

0.44

0.03

2.49E-50

6.14E-49

0.25

0.18

0.02

7.26E-21

7.65E-15

N-acetyl-1-methylhistidine

rs1052161

ALMS1

0.39

0.29

0.03

5.11E-27

2.63E-26

0.33

0.15

0.02

2.72E-18

1.35E-12

N-acetyl-1-methylhistidine

rs2272051

DUSP11

0.35

0.27

0.03

5.62E-23

1.44E-22

0.47

0.12

0.02

1.24E-12

2.89E-07

succinylcarnitine

rs2729835

LACTB

0.32

0.15

0.02

5.93E-21

1.33E-20

0.41

0.07

0.01

1.23E-07

1.39E-02
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Supplemental Table 3. Male common variants
traits

Name

Gene

maf.EA

beta.EA

se.EA

maf.AA

beta.AA

se.AA

aminooctanoate

rs3813227

ALMS1

0.24

-0.24

0.03

3.22E-13

5.10E-13

0.25

-0.19

0.03

4.09E-08

1.07E-02

aminooctanoate

rs6546837

ALMS1

0.24

-0.24

0.03

3.22E-13

5.10E-13

0.25

-0.19

0.03

4.83E-08

1.14E-02

aminooctanoate

rs6546838

ALMS1

0.24

-0.24

0.03

7.13E-13

9.68E-13

0.27

-0.20

0.03

8.07E-09

2.48E-03

aminooctanoate

rs6546839

ALMS1

0.24

-0.24

0.03

7.13E-13

9.68E-13

0.25

-0.19

0.03

4.17E-08

1.07E-02

aminooctanoate

rs2056486

ALMS1

0.24

-0.24

0.03

3.22E-13

5.10E-13

0.27

-0.20

0.03

8.07E-09

2.48E-03

aminooctanoate

rs10193972

ALMS1

0.24

-0.24

0.03

3.22E-13

5.10E-13

0.26

-0.20

0.03

8.06E-09

2.48E-03

aminooctanoate

rs1052161

ALMS1

0.38

-0.19

0.03

4.59E-10

5.81E-10

0.34

-0.25

0.03

1.33E-15

5.33E-09

aminooctanoate

rs1805074

DMGDH

0.30

-0.11

0.03

8.63E-05

9.11E-05

0.48

-0.12

0.02

6.65E-08

1.48E-02

aminooctanoate

rs1805073

DMGDH

0.30

-0.11

0.03

8.63E-05

9.11E-05

0.49

-0.12

0.02

4.30E-08

1.07E-02

N1-methyladenosine

rs11555566

ADA

0.06

0.22

0.05

9.71E-06

1.15E-05

0.07

0.18

0.03

2.09E-07

3.97E-02

N-acetyl-1-methylhistidine

rs3813227

ALMS1

0.24

0.49

0.03

7.86E-52

3.73E-51

0.25

0.17

0.02

2.57E-11

1.56E-05

N-acetyl-1-methylhistidine

rs6546837

ALMS1

0.24

0.49

0.03

7.86E-52

3.73E-51

0.25

0.17

0.02

3.12E-11

1.56E-05

N-acetyl-1-methylhistidine

rs6546838

ALMS1

0.24

0.48

0.03

2.32E-51

7.35E-51

0.27

0.17

0.02

3.49E-12

2.79E-06

N-acetyl-1-methylhistidine

rs6546839

ALMS1

0.24

0.48

0.03

2.32E-51

7.35E-51

0.25

0.17

0.03

3.01E-11

1.56E-05

N-acetyl-1-methylhistidine

rs2056486

ALMS1

0.24

0.49

0.03

7.86E-52

3.73E-51

0.27

0.17

0.02

3.49E-12

2.79E-06

N-acetyl-1-methylhistidine

rs10193972

ALMS1

0.24

0.49

0.03

7.86E-52

3.73E-51

0.26

0.17

0.02

3.35E-12

2.79E-06

N-acetyl-1-methylhistidine

rs1052161

ALMS1

0.38

0.28

0.03

6.47E-23

1.76E-22

0.34

0.17

0.02

3.67E-14

7.33E-08

N-acetyl-1-methylhistidine

rs2272051

DUSP11

0.35

0.24

0.03

4.30E-17

1.02E-16

0.49

0.12

0.02

5.88E-09

2.35E-03
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Supplemental Table 4. Sex-specific burden test
EA
sex

traits

gene

chr

male

dimethylglycine

DMGDH

5

male

N-acetylalanine

ACY1

female

N-acetylalanine

ACY1

female

isobutyrylcarnitine

female

N

AA

nsnp

MAC

beta

se

p

Fdr-q

N

nsnp

701

6

26

0.64

0.10

1.48E-11

4.59E-10

720

10

3

701

3

15

0.23

0.04

6.00E-08

9.30E-07

720

3

827

3

17

0.23

0.04

8.22E-10

1.64E-08

ACAD8

11

827

1

39

0.46

0.09

1.44E-07

indolelactate

CCBL1

9

827

3

17

0.29

0.07

female

dimethylglycine

DMGDH

5

827

6

39

0.28

female

N-acetylthreonine

ACY1

3

827

3

17

female

phenyllactate (PLA)

CCBL1

9

827

3

17

female

3-(4-hydroxyphenyl)lactate

CCBL1

9

827

3

17

MAC

beta

se

p

Fdr-q

26

0.44

0.07

1.73E-09

1.21E-03

5

81

0.15

0.02

1.63E-13

5.68E-07

1292

7

151

0.17

0.02

1.06E-27

2.03E-21

1.44E-06

1292

3

90

0.32

0.05

3.25E-10

2.07E-04

2.41E-05

1.61E-04

1292

9

36

0.36

0.05

1.65E-12

2.10E-06

0.08

0.000389

1.94E-03

1292

11

66

0.58

0.05

2.36E-29

9.02E-23

0.23

0.08

0.001936

6.74E-03

1292

7

151

0.13

0.02

2.77E-08

8.83E-03

0.23

0.07

0.002022

6.74E-03

1292

9

36

0.29

0.05

1.28E-08

5.46E-03

0.23

0.08

0.002634

7.52E-03

1292

9

36

0.29

0.05

2.33E-08

8.09E-03

FDR-q

Supplemental Table 5. Z test for sex-specific burden test
EA
chr

cmafUsed.male

AA

traits

Gene

Z.tst

p.val

leucylleucine

NMT2

10

0.009

cmafUsed.female
0.007

Z.tst
-0.66

0.51

0.003

0.004

-5.45

4.97E-08

0.03

10-nonadecenoate (19:1n9)

AGER

6

0.059

0.053

-1.50

0.13

0.051

0.040

5.66

1.56E-08

0.03

phenylalanylphenylalanine

BAG4

8

0.008

0.007

-1.22

0.22

0.003

0.004

-5.51

3.59E-08

0.03

phenylalanylphenylalanine

SPATA17

1

0.027

0.026

-0.61

0.54

0.019

0.018

-5.60

2.13E-08

0.03

S-methylcysteine

IKZF4

12

0.010

0.008

0.10

0.92

0.003

0.008

-5.57

2.54E-08

0.03
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Appendix B. supplemental materials for Chapter 3
Supplemental Table 1. List of 271 metabolites and transformation methods applied
Metabolites

Super_Pathway

Sub_Pathway

Platform

Transformation

alanine
asparagine
aspartate
N-acetylalanine
creatine
creatinine
glutamate
pyroglutamine
5-oxoproline
betaine
dimethylglycine
glycine
N-acetylglycine
N-acetylthreonine
serine
threonine
4-guanidinobutanoate
3-methylhistidine
histidine
N-acetyl-1-methylhistidine
trans-urocanate
2-methylbutyrylcarnitine (C5)
3-hydroxyisobutyrate
3-methyl-2-oxovalerate
alpha-hydroxyisovalerate
beta-hydroxyisovalerate
beta-hydroxyisovaleroylcarnitine
isobutyrylcarnitine
isoleucine
isovalerate
isovalerylcarnitine
leucine
tiglyl carnitine
valine

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Alanine and Aspartate Metabolism
Creatine Metabolism
Creatine Metabolism
Glutamate Metabolism
Glutamate Metabolism
Glutathione Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Glycine, Serine and Threonine Metabolism
Guanidino and Acetamido Metabolism
Histidine Metabolism
Histidine Metabolism
Histidine Metabolism
Histidine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism
Leucine, Isoleucine and Valine Metabolism

LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
not transformed
not transformed
natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
natural log
natural log
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glutarate (pentanedioate)
glutarylcarnitine (C5)
lysine
N6-acetyllysine
pipecolate

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

2-aminobutyrate

Amino Acid

2-hydroxybutyrate (AHB)

Amino Acid

methionine sulfoxide

Amino Acid

S-methylcysteine
3-(4-hydroxyphenyl)lactate
3-methoxytyrosine
3-phenylpropionate (hydrocinnamate)
N-acetylphenylalanine
o-cresol sulfate
p-cresol sulfate
phenol sulfate
phenylacetate
phenylacetylglutamine
phenylalanine
phenyllactate (PLA)
tyrosine
acisoga
3-indoxyl sulfate
anthranilate
indoleacetate
indolelactate
indolepropionate
kynurenine
serotonin (5HT)
tryptophan
tryptophan betaine
arginine
citrulline
homocitrulline
N-methylproline

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid

Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Lysine Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Methionine, Cysteine, SAM and Taurine
Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Phenylalanine and Tyrosine Metabolism
Polyamine Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Tryptophan Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
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LC/MS Polar
LC/MS Pos
LC/MS Polar
LC/MS Pos
LC/MS Pos

rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

LC/MS Pos

rank based inverse normal

GC/MS

natural log

LC/MS Polar

rank based inverse normal

LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal

ornithine
pro-hydroxy-pro
proline
trans-4-hydroxyproline
urea
erythronate
glucuronate
trehalose
mannitol
mannose

Amino Acid
Amino Acid
Amino Acid
Amino Acid
Amino Acid
Carbohydrate
Carbohydrate
Carbohydrate
Carbohydrate
Carbohydrate

1,5-anhydroglucitol (1,5-AG)

Carbohydrate

glucose

Carbohydrate

glycerate

Carbohydrate

lactate
arabinose
threitol
arabonate
threonate
bilirubin (E,E)
N1-Methyl-2-pyridone-5-carboxamide
pantothenate
alpha-tocopherol
gamma-tocopherol
pyridoxate
phosphate
citrate
malate
succinate
succinylcarnitine
carnitine
deoxycarnitine
5-HETE

Carbohydrate
Carbohydrate
Carbohydrate
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Cofactors and Vitamins
Energy
Energy
Energy
Energy
Energy
Lipid
Lipid
Lipid

propionylcarnitine
acetylcarnitine

Lipid
Lipid

Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Urea cycle; Arginine and Proline Metabolism
Aminosugar Metabolism
Aminosugar Metabolism
Disaccharides and Oligosaccharides
Fructose, Mannose and Galactose Metabolism
Fructose, Mannose and Galactose Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Glycolysis, Gluconeogenesis, and Pyruvate
Metabolism
Pentose Metabolism
Pentose Metabolism
Ascorbate and Aldarate Metabolism
Ascorbate and Aldarate Metabolism
Hemoglobin and Porphyrin Metabolism
Nicotinate and Nicotinamide Metabolism
Pantothenate and CoA Metabolism
Tocopherol Metabolism
Tocopherol Metabolism
Vitamin B6 Metabolism
Oxidative Phosphorylation
TCA Cycle
TCA Cycle
TCA Cycle
TCA Cycle
Carnitine Metabolism
Carnitine Metabolism
Eicosanoid
Fatty Acid Metabolism (also BCAA
Metabolism)
Fatty Acid Metabolism(Acyl Carnitine)
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LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Polar
LC/MS Pos
LC/MS Polar
LC/MS Polar
GC/MS
GC/MS
LC/MS Polar

rank based inverse normal
natural log
natural log
natural log
natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal

LC/MS Neg

rank based inverse normal

LC/MS Polar

rank based inverse normal

LC/MS Polar

rank based inverse normal

LC/MS Neg
GC/MS
GC/MS
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Pos
LC/MS Pos
GC/MS
GC/MS
LC/MS Neg
GC/MS
GC/MS
LC/MS Neg
LC/MS Polar
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg

natural log
rank based inverse normal
natural log
rank based inverse normal
not transformed
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal

LC/MS Pos
LC/MS Pos

rank based inverse normal
rank based inverse normal

cis-4-decenoyl carnitine
decanoylcarnitine
hexanoylcarnitine
hydroxybutyrylcarnitine
laurylcarnitine
octanoylcarnitine
oleoylcarnitine
palmitoylcarnitine
stearoylcarnitine
2-aminoheptanoate
2-aminooctanoate
2-hydroxyglutarate
3-carboxy-4-methyl-5-propyl-2furanpropanoate (CMPF)
adipate
azelate (nonanedioate)
dodecanedioate
eicosanodioate
hexadecanedioate
octadecanedioate
sebacate (decanedioate)
suberate (octanedioate)
tetradecanedioate
undecanedioate
13-HODE + 9-HODE
2-hydroxypalmitate
2-hydroxystearate
glycerol
glycerol 3-phosphate (G3P)
inositol 1-phosphate (I1P)
myo-inositol
scyllo-inositol
3-hydroxybutyrate (BHBA)
10-heptadecenoate (17:1n7)
10-nonadecenoate (19:1n9)
eicosenoate (20:1n9 or 11)
margarate (17:0)
myristate (14:0)
myristoleate (14:1n5)

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid Metabolism(Acyl Carnitine)
Fatty Acid, Amino
Fatty Acid, Amino
Fatty Acid, Dicarboxylate

LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
GC/MS

natural log
natural log
rank based inverse normal
natural log
natural log
natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Dicarboxylate
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Fatty Acid, Monohydroxy
Glycerolipid Metabolism
Glycerolipid Metabolism
Inositol Metabolism
Inositol Metabolism
Inositol Metabolism
Ketone Bodies
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid

LC/MS Neg
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
GC/MS
LC/MS Polar
GC/MS
LC/MS Polar
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
natural log
natural log
natural log
natural log
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nonadecanoate (19:0)
oleate (18:1n9)
palmitate (16:0)
palmitoleate (16:1n7)
stearate (18:0)
1-arachidonoylglycerophosphocholine
(20:4n6)
1arachidonoylglycerophosphoethanolamine
1-arachidonoylglycerophosphoinositol
1-docosahexaenoylglycerophosphocholine
(22:6n3)
1docosahexaenoylglycerophosphoethanolami
ne
1-docosapentaenoylglycerophosphocholine
(22:5n3)
1-linoleoylglycerophosphoethanolamine
1-oleoylglycerophosphocholine (18:1)
1-palmitoleoylglycerophosphocholine
(16:1)
1-palmitoylglycerophosphoinositol
1-palmitoylplasmenylethanolamine
1-stearoylglycerophosphoethanolamine
2-arachidonoylglycerophosphocholine
2-linoleoylglycerophosphoethanolamine
2-myristoylglycerophosphocholine
5-dodecenoate (12:1n7)
caprate (10:0)
caproate (6:0)
heptanoate (7:0)
laurate (12:0)
pelargonate (9:0)
1-oleoylglycerol (1-monoolein)
1-stearoylglycerol (1-monostearin)
choline
glycerophosphorylcholine (GPC)
adrenate (22:4n6)
arachidonate (20:4n6)

Lipid
Lipid
Lipid
Lipid
Lipid

Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid
Long Chain Fatty Acid

LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

rank based inverse normal
not transformed
not transformed
natural log
rank based inverse normal

Lipid

Lysolipid

LC/MS Pos

rank based inverse normal

Lipid
Lipid

Lysolipid
Lysolipid

LC/MS Neg
LC/MS Neg

natural log
natural log

Lipid

Lysolipid

LC/MS Pos

natural log

Lipid

Lysolipid

LC/MS Neg

rank based inverse normal

Lipid
Lipid
Lipid

Lysolipid
Lysolipid
Lysolipid

LC/MS Pos
LC/MS Neg
LC/MS Pos

natural log
natural log
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Lysolipid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Medium Chain Fatty Acid
Monoacylglycerol
Monoacylglycerol
Phospholipid Metabolism
Phospholipid Metabolism
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)

LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg

natural log
natural log
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
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dihomo-linoleate (20:2n6)
dihomo-linolenate (20:3n3 or n6)
docosahexaenoate (DHA; 22:6n3)
docosapentaenoate (n3 DPA; 22:5n3)
docosapentaenoate (n6 DPA; 22:5n6)
eicosapentaenoate (EPA; 20:5n3)
linoleate (18:2n6)
linolenate [alpha or gamma; (18:3n3 or 6)]
stearidonate (18:4n3)
glycochenodeoxycholate
glycocholate
taurochenodeoxycholate
glycocholenate sulfate
glycodeoxycholate
glycolithocholate sulfate
glycoursodeoxycholate
taurocholenate sulfate
taurolithocholate 3-sulfate
21-hydroxypregnenolone disulfate
4-androsten-3beta,17beta-diol disulfate (1)
4-androsten-3beta,17beta-diol disulfate (2)
5alpha-androstan-3beta,17beta-diol
disulfate
5alpha-pregnan-3beta,20alpha-diol disulfate
androsterone sulfate
cortisol
cortisone
dehydroisoandrosterone sulfate (DHEA-S)
epiandrosterone sulfate
pregn steroid monosulfate
pregnen-diol disulfate
7-alpha-hydroxy-3-oxo-4-cholestenoate (7Hoca)
cholesterol

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Polyunsaturated Fatty Acid (n3 and n6)
Primary Bile Acid Metabolism
Primary Bile Acid Metabolism
Primary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Secondary Bile Acid Metabolism
Steroid
Steroid
Steroid

LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

natural log
natural log
rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid

Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid
Steroid

LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg

rank based inverse normal
natural log
rank based inverse normal
natural log
natural log
natural log
rank based inverse normal
natural log
natural log

Lipid
Lipid

LC/MS Neg
GC/MS

rank based inverse normal
rank based inverse normal

hypoxanthine

Nucleotide

LC/MS Neg

rank based inverse normal

urate

Nucleotide

Sterol
Sterol
Purine Metabolism, (Hypo)Xanthine/Inosine
containing
Purine Metabolism, (Hypo)Xanthine/Inosine
containing

LC/MS Neg

rank based inverse normal
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xanthine
N1-methyladenosine
guanosine
5-methyluridine (ribothymidine)
N-acetyl-beta-alanine
pseudouridine
uridine
alanylleucine
arginylleucine
arginylphenylalanine
glycylleucine
glycylphenylalanine
glycylvaline
histidylleucine
leucylalanine
leucylasparagine
leucylglycine
leucylleucine
leucylserine
phenylalanylglutamate
phenylalanylleucine
phenylalanylphenylalanine
phenylalanylserine
pyroglutamylglycine
serylleucine
N-acetylcarnosine
DSGEGDFXAEGGGVR
gamma-glutamylalanine
gamma-glutamylglutamate
gamma-glutamylisoleucine
gamma-glutamylleucine
gamma-glutamylphenylalanine
gamma-glutamylthreonine
gamma-glutamyltyrosine
gamma-glutamylvaline
HWESASLLR
2-hydroxyhippurate (salicylurate)
3-methyl catechol sulfate (1)

Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Nucleotide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Peptide
Xenobiotics
Xenobiotics

Purine Metabolism, (Hypo)Xanthine/Inosine
containing
Purine Metabolism, Adenine containing
Purine Metabolism, Guanine containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Pyrimidine Metabolism, Uracil containing
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide
Dipeptide Derivative
Fibrinogen Cleavage Peptide
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Gamma-glutamyl Amino Acid
Polypeptide
Benzoate Metabolism
Benzoate Metabolism
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LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg

rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log

4-hydroxyhippurate
4-methylcatechol sulfate
4-vinylphenol sulfate
catechol sulfate
hippurate
methyl-4-hydroxybenzoate sulfate
O-methylcatechol sulfate
propyl 4-hydroxybenzoate sulfate
1,2-propanediol
2-hydroxyisobutyrate
3-hydroxypyridine sulfate
O-sulfo-L-tyrosine
salicylate
erythritol
gluconate
homostachydrine
piperine
stachydrine
thymol sulfate
1,7-dimethylurate
1-methylurate
5-acetylamino-6-amino-3-methyluracil
caffeine
paraxanthine
theobromine
theophylline

Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics
Xenobiotics

Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Benzoate Metabolism
Chemical
Chemical
Chemical
Chemical
Drug
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Food Component/Plant
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
Xanthine Metabolism
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LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
GC/MS
LC/MS Neg
LC/MS Neg
LC/MS Neg
GC/MS
LC/MS Polar
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Neg
LC/MS Neg
LC/MS Pos
LC/MS Neg
LC/MS Pos
LC/MS Pos
LC/MS Pos
LC/MS Pos

natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
natural log
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal
rank based inverse normal

Supplemental Table 2. Genes discovered through jointly testing the genetic main effects and gene-sex interactions
Fix.pvalu
e

AA
Random.
pvalue

Joint.pva
lue

Fdr.p.joi
nt

N_S
NP

Fix.pvalu
e

EA
Random.
pvalue

Joint.pva
lue

Postfdr.p
.joint

Metabolites

Gene

Chr

N_S
NP

2-aminooctanoate

ALMS1

2

52

5.24E-02

1.26E-01

2.16E-07

2.28E-02

37

5.24E-02

3.02E-02

2.15E-03

8.17E-03

2-aminooctanoate

ACY1

3

7

2.64E-02

2.89E-02

2.19E-08

4.63E-03

3

4.93E-02

6.23E-02

1.29E-01

1.96E-01

arachidonate (20:4n6)
1arachidonoylglyceropho
sphoethanolamine

PLA2G7

6

7

6.50E-01

6.67E-01

6.19E-07

4.62E-02

7

1.68E-02

1.25E-02

1.86E-02

5.06E-02

MAP10

1

13

4.11E-03

4.22E-03

1.72E-07

1.94E-02

5

6.11E-01

7.62E-01

6.88E-01

7.68E-01

arginylleucine

NPC2

14

4

9.95E-02

8.02E-02

5.26E-07

4.34E-02

5

2.22E-01

4.75E-01

1.79E-01

2.61E-01

arginylleucine

NDRG3

20

4

2.79E-01

2.26E-01

4.55E-08

6.69E-03

NA

NA

NA

NA

NA

cholesterol

PCSK9

1

18

9.52E-01

9.59E-01

6.90E-10

2.12E-04

6

6.84E-01

6.04E-01

6.72E-02

1.14E-01

deoxycarnitine

SLC25A45

11

8

6.48E-01

6.62E-01

1.70E-07

1.94E-02

5

3.89E-01

4.51E-01

4.37E-03

1.51E-02

deoxycarnitine

C1QTNF1

17

5

9.57E-03

7.16E-03

6.29E-07

4.62E-02

5

6.66E-01

7.47E-01

2.45E-01

3.21E-01

dimethylglycine
DSGEGDFXAEGGGV
R

DMGDH

5

12

8.01E-02

6.50E-02

4.57E-36

7.73E-30

8

6.23E-01

6.33E-01

2.56E-09

1.95E-08

CPN1

10

3

9.52E-01

9.14E-01

5.25E-10

1.77E-04

NA

NA

NA

NA

NA

eicosanodioate
gammaglutamylphenylalanine

ALDH7A1

5

8

8.55E-07

5.64E-07

5.62E-07

4.52E-02

4

1.80E-01

1.70E-01

3.12E-01

3.82E-01

COPE

19

3

7.02E-08

7.53E-08

9.65E-08

1.31E-02

3

5.60E-01

6.91E-01

8.47E-01

8.70E-01

glutarylcarnitine (C5)
glycochenodeoxycholat
e

RNASEH2A

19

5

5.05E-01

4.98E-01

2.88E-08

5.72E-03

3

9.32E-01

9.20E-01

2.65E-01

3.35E-01

SLC10A1

14

8

2.11E-01

2.96E-01

5.75E-07

4.52E-02

NA

NA

NA

NA

NA

glycocholate

LRP4

11

18

7.30E-06

5.14E-06

3.98E-07

3.54E-02

12

9.37E-01

9.48E-01

9.89E-01

9.89E-01

glycocholate

SLC10A1

14

8

1.81E-01

2.44E-01

2.01E-10

8.52E-05

NA

NA

NA

NA

NA

glycocholenate sulfate

CYP27A1

2

12

9.12E-01

9.08E-01

1.34E-07

1.74E-02

7

3.26E-01

3.57E-01

6.22E-02

1.13E-01

glycocholenate sulfate

HRASLS5

11

6

7.41E-01

7.93E-01

3.24E-08

5.78E-03

7

9.12E-02

1.29E-01

2.26E-01

3.07E-01
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glycocholenate sulfate

SLCO1B1

12

9

9.60E-01

9.42E-01

1.26E-08

2.84E-03

NA

NA

NA

NA

NA

hexadecanedioate

SLCO1B1

12

9

2.28E-01

2.39E-01

5.25E-10

1.77E-04

NA

NA

NA

NA

NA

histidine

HAL

12

11

9.90E-01

9.84E-01

7.07E-07

4.98E-02

14

1.66E-01

1.61E-01

8.69E-04

4.13E-03

histidylleucine

NPC2

14

4

1.70E-03

1.25E-03

3.74E-08

6.02E-03

5

1.35E-01

2.73E-01

4.83E-02

9.67E-02

13-HODE + 9-HODE
3-(4hydroxyphenyl)lactate

PLA2G7

6

7

7.24E-02

7.82E-02

3.44E-08

5.81E-03

7

3.57E-01

4.03E-01

5.85E-01

6.74E-01

CCBL1

9

9

8.97E-01

9.40E-01

4.57E-14

2.57E-08

4

7.91E-01

7.87E-01

2.51E-02

6.11E-02

indolelactate

CCBL1

9

9

5.77E-01

6.23E-01

5.15E-23

5.81E-17

4

3.38E-01

2.99E-01

2.70E-04

1.47E-03

isobutyrylcarnitine

ACAD8

11

3

3.87E-01

4.08E-01

6.98E-13

3.37E-07

3

1.91E-01

1.99E-01

2.58E-10

2.45E-09

kynurenine

ZNF827

4

8

1.66E-02

2.52E-02

2.50E-07

2.48E-02

7

4.31E-01

3.74E-01

3.71E-02

8.28E-02

kynurenine

IDO1

8

6

8.57E-01

8.95E-01

3.99E-09

1.05E-03

NA

NA

NA

NA

NA

leucylasparagine

KLKB1

4

13

4.52E-01

4.65E-01

4.87E-07

4.12E-02

10

1.61E-01

1.37E-01

1.75E-02

5.06E-02

leucylglycine

NDRG3

20

4

7.57E-01

6.56E-01

7.84E-08

1.10E-02

NA

NA

NA

NA

NA

leucylserine
linolenate [alpha or
gamma; (18:3n3 or 6)]
4-methylcatechol
sulfate

NPC2

14

4

5.83E-04

3.79E-04

1.93E-07

2.10E-02

5

2.93E-02

6.59E-02

6.78E-03

2.15E-02

COL3A1

2

13

2.05E-01

2.37E-01

1.41E-07

1.76E-02

7

1.04E-01

9.31E-02

4.01E-02

8.47E-02

PSME4

2

12

8.52E-01

8.58E-01

6.18E-09

1.49E-03

9

5.27E-01

5.06E-01

7.36E-01

7.93E-01

N1-methyladenosine
N-acetyl-1methylhistidine
N-acetyl-1methylhistidine

ADA

20

5

5.64E-02

5.59E-02

2.69E-07

2.60E-02

NA

NA

NA

NA

NA

ALMS1

2

52

9.88E-01

9.77E-01

4.05E-09

1.05E-03

37

4.60E-01

4.45E-01

3.32E-11

4.21E-10

DDTL

22

2

3.65E-08

1.18E-07

2.24E-07

2.29E-02

NA

NA

NA

NA

NA

N-acetylalanine

ACY1

3

7

3.76E-01

3.82E-01

4.43E-52

1.50E-45

3

4.65E-01

4.74E-01

4.07E-23

1.55E-21

N-acetylalanine

ADCY5

3

7

1.06E-06

1.71E-06

7.02E-07

4.98E-02

9

2.72E-01

2.96E-01

6.90E-02

1.14E-01

N-acetyl-beta-alanine

CRYGA

2

4

6.98E-01

8.47E-01

4.38E-07

3.80E-02

4

1.99E-01

2.06E-01

3.50E-01

4.16E-01

N-acetyl-beta-alanine

PTER

10

7

6.20E-01

5.55E-01

3.07E-08

5.77E-03

4

9.58E-02

8.68E-02

9.84E-12

1.87E-10

N-acetylcarnosine

SEPT-9

17

3

4.60E-02

8.83E-02

3.31E-07

3.11E-02

6

1.56E-01

1.85E-01

2.23E-01

3.07E-01
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N-acetylglycine

ACY1

3

7

3.30E-01

3.28E-01

3.93E-08

6.05E-03

3

7.68E-01

7.81E-01

1.58E-03

6.66E-03

N-acetylthreonine
10-nonadecenoate
(19:1n9)

ACY1

3

7

2.68E-01

2.72E-01

8.01E-16

6.77E-10

3

2.39E-01

2.53E-01

2.71E-05

1.72E-04

AGER

6

7

4.32E-07

2.16E-07

3.95E-07

3.54E-02

9

4.06E-01

3.25E-01

5.74E-02

1.09E-01

phenyllactate (PLA)

CCBL1

9

9

4.13E-01

4.66E-01

2.73E-14

1.85E-08

4

4.43E-01

3.76E-01

2.57E-02

6.11E-02

taurocholenate sulfate

OR2C3

1

7

6.14E-07

4.38E-07

6.26E-07

4.62E-02

3

5.91E-01

5.65E-01

7.51E-01

7.93E-01

tiglyl carnitine

DARS

2

6

7.52E-06

2.75E-06

1.53E-07

1.85E-02

2

1.47E-01

1.16E-01

7.61E-02

1.21E-01
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Supplemental Table 3 Genes revealed as suggestively significant (false discovery rate <20%) through rareGE fix/random effect
interaction test

Metabolites
gammaglutamylphenylalanine

Gene

Chr

AA
N_S
NP

Fix.pvalu
e

Random.pvalu
e

Fdr.fix.
p

Fdr.random.
p

EA
N_SN
P

Fix.pvalu
e

Random.pvalu
e

COPE

19

3

7.02E-08

7.53E-08

0.12

0.20

3

0.56

0.69

N-acetyl-1-methylhistidine

DDTL

22

2

3.65E-08

1.18E-07

0.12

0.20

NA

NA

NA

arginylleucine

SPACA4

19

2

1.33E-07

2.77E-05

0.15

0.73

NA

NA

NA

Supplemental Table 4 Genes revealed as suggestively significant (false discovery rate <20%) through MiSTi interaction test

Metabolites
bilirubin
(E,E)
N-acetyl1-methylhistidine
arginylleu
cine
arginylleu
cine

Gene

Ch
r
P

OLH

Fisher.p
value
5

6
2

D
DTL

AA
N_S
NP

2

.18E-08
7
5
.41E-08
2

G

1

NL1

6
1

P
TPN5

1

.21E-07
3
1
.86E-07
3

BurdenComp.
pvalue
2.14E
-05
8.64E
-04
1.15E
-02
5.11E
-04

VarComp.p
value
1.16
E-04
3.01
E-06
5.30
E-07
1.87
E-05
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Fdr.Fish
er.p
0
.09
0
.09
0
.13
0
.15

EA
N_SN
P

Fisher.
pvalue

BurdenComp
.pvalue

VarComp.p
value

0

A

4 .57
N
A

0.46

0.51

NA

NA

0.87

0.21

NA

NA

N
0

A

5 .49
N
A

N

Supplemental Figure 1. QQ plots of joint test results for each metabolite
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119

120

121

122
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124

125

126

127

128

129

130

131

132

133

134
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